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ABSTRACT 
Microbial translocation and increased immune activation have been involved in functional T cell 
impairments and disease progression during HIV-1 infection. The impact of microbial translocation on 
the phenotype of memory B cells in HIV-1 infected patients was studied in paper I. The expression of 
activation marker IL-21R was higher in HIV-1 infected patients compared with controls. An inverse 
correlation was observed between IL-21R expression and frequency of resting memory (RM) B cells in 
blood; IL-21R+ RM B cells were more sensitive to apoptosis and their frequency correlated with sCD14, 
a marker of microbial translocation. Furthermore, TLR triggering by microbial products resulted in IL-
21R expression on memory B cells in vitro. These results suggest a direct link between microbial 
translocation and an impaired B cell phenotype.  
In paper II we showed that IL-7 induced upregulation of CD70 expression on T cells. Increased CD70 
expression, by triggering the CD27 receptor on B cells, can lead to alteration of the B cell phenotype and 
IgG production. In addition, IL-7 led to an increased production of BAFF by T cells, which enhanced B 
cell survival in vitro. In the context of HIV-1 infection, the mechanisms mediated by increased CD70 
expression on T cells might be implicated in establishment of B cell activation, a characteristic of 
immune pathology in infected patients. The role of CD70 in B cell dysfunction during HIV-1 infection 
was further studied in paper III. We found an increased expression of CD70 on CD4+ T cells which 
correlated with CD4+ T cell depletion and viremia in HIV-1 infected patients. CD4+ CD70+ T cells 
expressed pro-inflammatory cytokines and, based on their chemokine profile, it was predicted that they 
can migrate to sites of inflammation. A potential role for CD4+ CD70+ T cells in B cell activation in 
HIV-1 infected individuals was suggested by the association with CD38 and CD95 expression in memory 
B cells, with increased B cell proliferation and plasma IgG levels. The mechanism leading to CD70 up-
regulation on T cells during HIV-1 infection remains elusive. 
Although treatment with ART can lead to a nearly complete suppression of HIV-1 replication, ART does 
not fully target the increased immune activation found in HIV-1 infected patients. We showed in paper 
IV that ART initiation during primary HIV-1 infection (PHI) (early ART=EA) did not prevent the 
establishment of phenotypical changes of T cells, previously reported in HIV-1 infected patients starting 
treatment during the chronic phase of infection (late ART=LA). The phenotypical changes of T cells, 
comparable in the EA and LA groups, consisted in increased expression of immune activation markers 
HLA-DR and CD38 and reduced expression of CD127, which characterizes differentiated CD8+ T cells. 
It is worrisome that ART initiation during PHI does not correct for abnormal immune activation. It is 
however interesting that the number of HIV-1 DNA copies in blood of EA patients was significantly 
lower compared to LA patients; the correlation between T cell phenotype and size of the HIV-1 reservoir 
should be studied further. The frequency of B cell sub-populations in blood of EA and LA patients did 
not differ (preliminary results) and was not significantly altered compared to non-infected controls. 
 
 
 
2 
 
CONTENTS 
1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) ....................................................... 1 
1.1 The discovery of HIV ............................................................................................ 1 
1.2 Epidemiology ........................................................................................................ 1 
1.3 HIV-1 replication................................................................................................... 3 
1.4 Natural course of HIV-1 infection ........................................................................ 4 
1.4.1 HIV-1 transmission ................................................................................... 4 
1.4.2 Primary HIV-1 infection ........................................................................... 4 
1.4.3 Chronic HIV-1 infection ........................................................................... 6 
1.4.4 AIDS .......................................................................................................... 6 
1.5 Antiretroviral Therapy ........................................................................................... 6 
1.6 Latent HIV-1 reservoir .......................................................................................... 8 
2 ADAPTIVE IMMUNITY ............................................................................................ 11 
2.1 CD4+ and CD8+ T cells ...................................................................................... 11 
2.2 B cells .................................................................................................................. 11 
2.2.1 Co-stimulatory pathways regulating B cell responses ........................... 14 
2.3 Physiological role of molecules involved in HIV-1 pathogenesis and which 
will be discussed in the present thesis................................................................. 15 
3 HIV-1 PATHOGENESIS ............................................................................................. 17 
3.1 CD4+ T cell depletion ......................................................................................... 17 
3.1.1 Alterations in T helper cell subsets ......................................................... 18 
3.2 HIV-1 specific CD8+ T cell responses ............................................................... 20 
3.2.1 T cell exhaustion ..................................................................................... 20 
3.2.2 T cell senescence ..................................................................................... 21 
3.3 Chronic immune activation ................................................................................. 22 
3.3.1 HIV-1 induced collagen deposition in secondary LTs .......................... 23 
3.3.2 Microbial translocation ........................................................................... 24 
3.3.3 Reactivated infections which may increase immune activation ............ 24 
3.3.4 Markers of immune activation during HIV-1 infection ......................... 25 
3.4 B cell dysfunction during HIV-1 infection ......................................................... 25 
3.4.1 Direct and indirect effects of HIV-1 viremia on B cells ........................ 25 
3.4.2 Alterations in B-cell subsets ................................................................... 26 
3.4.3 Reduction of HIV-1 viremia by ART leads to normalization of some 
B cell dysfunction ................................................................................... 28 
4 AIMS OF THE THESIS ............................................................................................... 29 
5 RESULTS AND DISCUSSION ................................................................................... 30 
5.1 Paper I - Impact of microbial translocation and immune activation on B cell 
activation and loss of memory B cells in   HIV-1 infected patients .................. 30 
5.2 Paper II - Role of IL-7 on B cell activation and survival ................................... 34 
5.3 Paper III - Altered CD70 expression on T cells and its potential contribution 
to B cell abnormalities during HIV-1 infection .................................................. 38 
 
 
3 
 
5.4 Paper IV - ART initiated during primary HIV-1 infection and its impact on 
the establishment of abnormal phenotypic features of CD4+ and CD8+ T 
cells ...................................................................................................................... 44 
5.5 Preliminary results - Frequency of B cell sub-populations in the blood of EA 
and LA HIV-1 infected patients .......................................................................... 51 
6 CONCLUSIONS AND FUture DIRECTIONS ........................................................... 55 
7 MATERIALS AND METHODS ................................................................................. 60 
8 Acknowledgements ....................................................................................................... 64 
9 References ..................................................................................................................... 66 
 
  
 
 
4 
 
LIST OF ABBREVIATIONS 
 
2-LTR 2-long terminal repeat 
AID Activation-induced cytidine deaminase 
AIDS Acquired immune deficiency syndrome 
AM Activated memory 
APC Antigen-presenting cell 
APRIL A proliferation-inducing ligand 
ART Antiretroviral treatment 
BAFF B cell activating factor 
BAFFR BAFF receptor 
BCMA B cell maturation antigen 
BCR B cell receptor 
BM Bone marrow 
CCR C-C chemokine receptor 
CD Cluster of differentiation 
cDNA Complementary DNA 
CFSE Carboxyfluorescein succinimidyl ester 
CM Central memory 
CMV Cytomegalovirus 
CNS Central nervous system 
CTL Cytotoxic T lymphocyte 
CXCR C-X-C chemokine receptor 
DC Dendritic cell 
DNA Deoxyribonucleic acid 
EBV Epstein-Barr virus 
ELISA Enzyme-linked immunosorbent assay 
EM Effector memory 
FCR Fibroblastic reticular cell 
FDC Follicular dendritic cell 
GALT Gut-associated lymphoid tissue 
GC Germinal center 
GI tract Gastrointestinal tract 
gp Glycoprotein 
HIV Human immunodeficiency virus 
HIV-1 Human immunodeficiency virus type 1 
HIV-2 Human immunodeficiency virus type 2 
HLA Human leukocyte antigen 
ICOS Inducible costimulator 
Ig Immunoglobulin 
IL Interleukin 
IFN Interferon 
INP Intact-non-induced provirus 
LN Lymph node 
LPS Lipopolysaccharide 
LTNP Long-term non-progressor 
MHC Major histocompatibility complex 
MZ Marginal zone 
NHP Non-human primate 
NK Natural killer 
 
 
5 
 
NRTI Nucleoside reverse transcriptase inhibitor 
NNRTI Non-nucleoside reverse transcriptase inhibitor 
PCR Polymerase chain reaction 
PD-1 Programmed death-1 
PHI Primary HIV infection 
RM Resting memory 
RNA Ribonucleic acid 
RT Reverse transcriptase 
sCD14 Soluble CD14 
SHM Somatic hyper mutation 
SIV Simian immunodeficiency virus 
SLE Systemic lupus erythematosus 
TACI Transmembrane activator and CAML interactor 
TCR T cell receptor 
TD T cell-dependent 
TEMRA Effector memory RA 
Tfh Follicular T helper cell 
TGF Transforming growth factor 
TI T cell-independent 
TLM Tissue-like memory 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
Treg Regulatory T helper cell 
VL Viral load 
 
 

 
 
1 
 
1 HUMAN IMMUNODEFICIENCY VIRUS (HIV) 
 
1.1 The discovery of HIV 
More than three decades have passed since the first cases of acquired immune deficiency 
syndrome (AIDS) were reported in New York and San Francisco. At the beginning of the 
epidemics AIDS was thought to be a disease of homosexual men since previously healthy, 
young homosexual men were suffering from opportunistic infections and rare types of cancers, 
symptoms of an impaired immune system [1]. In 1983, two years after the first case was 
reported, the causative agent of AIDS was isolated [2] and later on named human 
immunodeficiency virus (HIV). HIV spread rapidly world- wide and cases in heterosexual 
persons and infants revealed that transmission could also occur through heterosexual contact and 
from infected pregnant mothers to their children [1]. HIV has of today infected more than 70 
million people, and about 34 million people have died of symptoms related to HIV infection [3]. 
The introduction of combination antiretroviral treatment (ART), approximately 20 years ago, 
was the beginning of a new era as the new treatment regime could rapidly reduce morbidity and 
mortality in HIV infected people. Although there has been an improvement in recent years for 
the access to ART in low-and middle-income countries, far too many people still die of AIDS-
related diseases [4] making the HIV epidemic one of our most important global health 
challenges. 
1.2 Epidemiology 
The HIV epidemic arose from multiple zoonotic infections of simian immunodeficiency virus 
(SIV) from African primates to humans in West and Central Africa at the beginning of the 1900s 
[5]. HIV is a lentivirus for which two types exist, HIV-1 and HIV-2. HIV-1 was transmitted to 
man from chimpanzees and HIV-2 from sooty mangabey monkeys. HIV-2 is predominantly 
restricted to West Africa and gives rise to a similar disease as HIV-1, but with a reduced 
transmission rate and less pathogenicity [5-7]. HIV-1 is distributed into groups M, N, O and P. 
Group M, which is the main group causing the global HIV pandemic, is further divided into nine 
subtypes (A-D, F-H, J and K) and many circulating recombinant forms. Subtype C predominates 
in Africa and India, whereas subtype B is more common in Western Europe, the United States 
and Australia [7, 8]. As a result of these epidemiological features and of the income of affected 
countries, most research has been made on HIV-1 subtype B. 
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In 2014, an estimated 36.9 million people were living with HIV (Figure 1); out of these 
individuals, around 2 million people were newly infected while 1.2 million people died of 
AIDS-related diseases [4]. The highest HIV/AIDS morbidity and mortality have been seen in 
developing countries, with young adults in sub-Saharan Africa experiencing the highest 
prevalence [5].  
As of June 2015, 15.8 million people were on ART globally, 41 % of all adults and 32 % of all 
children [4]. To take the AIDS response forward, UNAIDS has developed an ambitious 
approach to reach some targets by 2020. The targets include 90 % of all people being HIV-
positive knowing their status, 90 % of people who know their status having access to treatment 
and 90 % of people on ART being successfully treated with suppressed viral loads (VLs). Of the 
36.9 million people living globally with HIV 17.1 million are not aware of their HIV status, 
while around 22 million do not have access to HIV treatment, including 1.8 million children [9]. 
A recent report from the European Centre for Disease Prevention and Control concluded that 
many countries in Europe are still far away from achieving these goals while Sweden is the only 
country in Europe currently meeting all three targets. The UK is meeting two of these targets but 
not the one which expects >90% of those estimated to be living with HIV to be diagnosed [10]. 
 
 
Figure 1. Estimated number of adults and children living with HIV in 2014. Data from 
UNAIDS 2015 global statistics. 
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1.3 HIV-1 replication 
The HIV-1 replication cycle begins with the interaction of the glycoprotein gp120 on the virus 
and the CD4 molecule expressed mainly on activated T cells and the chemokine co-receptors 
CXCR4 or CCR5; X4-tropic HIV-1 strains use CXCR4 and R5-tropic HIV-1 strains use CCR5. 
Binding of the virus to either of these co-receptors leads to conformational changes of the virus 
glycoproteins resulting in the fusion of the viral membrane with the membrane of the target host. 
Other cells bearing the CD4 molecule and the co-receptors are also infected, including resting 
CD4+ T cells, dendritic cells (DCs), monocytes and macrophages. R5 viruses represent the 
major group of transmissible strains, whereas X4 viruses tend to arise later on in the course of 
the disease [11, 12]. In addition to gp120, the HIV-1 envelope complex consists of the 
transmembrane glycoprotein gp41, which is responsible for the fusion between the viral 
envelope and the host membrane; after fusion the virus enters the cytoplasm of the host where 
the viral enzyme called reverse transcriptase (RT) will enable the initiation of virus replication 
[11].  
A double stranded DNA copy of the viral RNA is synthesized by RT followed by the transfer of 
the viral DNA to the cell nucleus for its integration into the host genome with the help of the 
viral integrase enzyme. The integrated viral DNA is called provirus [13]. When an extrinsic 
stimulus activates the infected cell, the cell responds by turning on the transcription of its own 
genes and by producing cytokines. This process of cellular activation may also activate the 
provirus that will be transcribed to new viral RNAs and translated into viral proteins that 
translocate to the cell membrane to become new immature virus particles. The new viruses bud 
off and are released from the infected cells. In the final step of the HIV-1 replication cycle the 
virus mature and the protease enzyme cleaves the viral polyprotein giving rise to infectious 
virions ready to infect other cells [14, 15]. The lack of RT proofreading during the retro-
transcription process leads to HIV-1 RNA sequence with a high rate of mutations; this sloppy 
process of reverse transcription is responsible for virus escape from immune responses and 
development of drug resistant viruses [5].  
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1.4 NATURAL COURSE OF HIV-1 INFECTION 
 
1.4.1 HIV-1 transmission 
HIV-1 spreads by sexual contact across mucosal surfaces and by percutaneous and perinatal 
routes. Sexual contact between heterosexual individuals accounts for most transmissions, and 
HIV-1 is mainly a sexually transmitted disease [5, 16]. Both biological and behavioral factors 
influence the transmission risk; VL  is very high during primary infection and late clinical stages 
of HIV-1 infection and patients are therefore most infectious during those stages [16]. The 
presence of sexually transmitted infections, pregnancy and anal intercourse are other factors that 
increase HIV-1 sexual transmission while male circumcision is associated with a lower risk of 
transmitting HIV-1 [7]. Although there are tools available to lower the transmission risk close to 
zero, e.g. the use of condom or initiation of ART in all diagnosed HIV-1 infected patients, 
UNAIDS has identified discrimination against high risk groups such as iv-drug users, sex 
workers, men who have sex with men and stigma against HIV-1 infected individuals as the 
biggest barriers for people to be aware of their HIV-1 status, initiate treatment and access 
prevention measures [17].  
1.4.2 Primary HIV-1 infection 
After transmission, the virus disseminates and replicates quickly in lymphoid organs, a period 
known as the eclipse phase (Figure 2). This phase, which lasts up to 10 days, is when the 
infection takes place in target cells and organs, but before viral RNA  is detectable in the plasma 
[18, 19]. The burst of viremia is manifested in most patients by an acute HIV-1 syndrome, on 
average two weeks after primary encounter with the virus. This phase has been denominated as 
primary HIV-1 infection (PHI). This flu-like illness may last from a few days up to a month and 
is characterized by a sudden onset of fever, sore throat, skin rash, enlarged lymph nodes 
sometimes also with headache, night sweats and diarrhea. The symptoms of PHI may be mild 
enough to pass unnoticed. The viremia peaks at about three to four weeks post exposure [20], 
and at this time there is a massive depletion of CD4+ T cells, mainly in the gut associated 
lymphoid tissue (GALT) [21] (Figure 2). Latency is established, within days from initial 
infection [22, 23], and once the host cell is reactivated by various cytokines, a recall antigen or 
treatment interruption, latently infected cells are capable of producing infectious virus [24]. 
Subjects with PHI are maximally contagious due to high viral replication and during this period 
the risk of transmission is very high [25]. The first weeks following HIV-1 infection can be 
divided into distinct clinical stages based on viral replication and evolving antibody responses, 
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the so called Fiebig stages I-VI [26]. After the eclipse phase, HIV-1 RNA can be detected in the 
blood by polymerase chain reaction (PCR) (Fiebig stage I). Around seven days later tests to 
detect p24 antigen becomes positive (Fiebig stage II). The p24 antigen is a viral core protein 
which appears transiently in blood before the development of HIV-1 antibodies; p24 is measured 
by enzyme-linked immunosorbent assay (ELISA) [25]. Fiebig stage III occurs within 
approximately five days after the p24 antigen test scores positive and 1-2 weeks after the onset 
of primary HIV-1 infection; at stage III, HIV-1 antibodies reach levels detectable with sensitive 
ELISAs.  
Fiebig stage IV is characterized by an intermediate Western blot test positivity, where reactivity 
to two of the following three proteins p24, gp41 and gp120 occurs, approximately three days 
after the positive results of sensitive ELISA tests. After additional 7 days, or around 1 month 
after the initial HIV-1 infection, Fiebig stage V occurs, with a clearly positive Western blot test 
including the three protein bands detected in stage IV; at this stage however, there is still a lack 
of serum reactivity to polymerase 31 (p31). Stage VI has an open-ended duration, but includes a 
full Western blot reactivity with a positive p31 band around 100 days after initial HIV-1 
infection (Figure 2) [25, 26].  
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Figure 2.  Natural course of HIV-1 infection, adapted from [18]. 
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1.4.3 Chronic HIV-1 infection 
Within 3-6 months after infection with HIV-1, plasma viremia will decrease to a stable level, 
known as the viral-set point (Figure 2). Viral-set point levels are partially predictive of the 
disease progression rate: the higher the VL is at this stage, the faster disease progression in  
HIV-1 infected individuals not receiving ART [18, 21]. Host factors, such as different HLA 
alleles and mutations of the CCR5 receptor, are also playing a role when determining the rate of 
disease progression [27].  Chronic infection is characterized by a constant, or slowly increasing, 
level of viremia, whereas the CD4+ T cell count declines slowly in a linear manner. At this 
point, most patients are asymptomatic and unaware of their infection. This period normally lasts 
from 1 up to 10 years. Despite the term “latency” the infection is highly dynamic, with abundant 
CD4+ T cells being infected and killed every day [19].  
 
1.4.4 AIDS 
Eventually, as the CD4+ T cells decrease, the immune system deteriorates, the viral “steady 
state” is lost and viremia increases. When the number of CD4+ T cells declines below 200 
cells/μl, HIV-1 infection progresses to AIDS, in general 8-10 years from primary infection. By 
the time AIDS develops, the CD4+ T cell counts continue to decline and the VL rises further. 
The infected individual may experience several different opportunistic infections and 
development of rare cancers, which normally do not develop in HIV-1 non-infected individuals. 
Without treatment AIDS is soon culminating in death of the infected patient [19].  
 
1.5 Antiretroviral Therapy 
The introduction of ART regimens in the late 1990s dramatically increased the life expectancy 
of millions of HIV-1 infected individuals. HIV-1 infection was transformed from a progressive 
disease with a deadly outcome into a chronic controlled disease [7]. Antiretroviral drugs are 
divided into six different groups on the basis of the step of the virus life cycle they inhibit 
(Figure 3). 
Viral entry is the target for various classes of antiretroviral drugs, such as chemokine receptor 
antagonists that prevent the binding of gp120 to the co-receptor and inhibit entry of CCR5-tropic 
viruses, and fusion inhibitors, which bind to the surface protein gp41 on the virus. RT is a 
multifunctional enzyme which transforms the single-stranded HIV-1 viral RNA into double-
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stranded DNA; this enzyme is the target for two distinct classes of antiretroviral agents: the 
nucleoside reverse transcriptase inhibitors (NRTIs) and the non-nucleoside reverse transcriptase 
inhibitors (NNRTIs). The NRTIs and NNRTIs interact at different sites on the enzyme, which 
block the DNA polymerization activity and inhibit the generation of full-length viral DNA. 
Integrase inhibitors specifically inhibit the incorporation of the virus genome into the DNA of 
the host cell. Protease inhibitors block the proteolysis of the viral polyprotein, needed for 
generating infectious viral particles. Standard antiretroviral therapy regimens ususally combine 
two NRTIs with one NNRTI, integrase inhibitor or protease inhibitor. 
 
By combining three or four drugs from different groups long-term viral suppression is 
maintained and the risk for drug resistance is decreased [28, 29]. CD4+ T cell count and HIV-1 
RNA are the main markers used for evaluating the treatment regime.  Successful treatment is 
achieved when the levels of HIV-1 RNA in plasma decrease significantly within four weeks of 
treatment and to undetectable levels (< 50 copies/ml) within 3-6 months after initiation of 
treatment. In non-treated HIV-1 infected individuals levels of HIV-1 RNA can give some 
indication of disease progression, including how fast CD4+ T cells are expected to decrease. In 
addition, CD4+ T cell count after treatment initiation gives an indication of how compromised 
the immune system is. According to the latest WHO guidelines, ART should be introduced, 
independently of the CD4 T cell count, as soon as a patient has been diagnosed with HIV-1 or if 
there is a clinical suspicion of HIV-1 infection [30]. Increasing data have shown that the 
introduction of ART in the early asymptomatic phase of the infection is beneficial regarding the 
prevalence of both serious AIDS-related and non-AIDS related events [31] as well as in slowing 
down disease progression [32] and decreasing the size of the latent HIV-1 reservoir [22, 33, 34]. 
HIV-1 transmission is decreased to minimal levels when an infected individual is well treated, 
further confirming the advantage of initiating ART in the primary phase of infection [30]. 
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 Figure 3. Schematic overview of the HIV-1 replication cycle and the classes of antiretroviral 
drugs blocking the different steps of virus replication. Adapted from [15]. 
 
1.6 Latent HIV-1 reservoir 
Although ART is efficient in suppressing VL below levels of detection and restoring CD4+ T 
cell counts it is not curative as of the persistence of a latent viral reservoir mainly in resting 
memory CD4+ T cells [35-37]. The reservoir is established during early infection when the virus 
infects activated CD4+ T cells which  then  return to a resting memory state [38]. A recent study 
has shown that latency can also be established directly in resting CD4+ T cells, suggesting that 
virus infection of both activated and resting CD4+ T cells contribute to virus latency [39]. 
Resting memory cells are keeping the viral genome in an integrated form that, in its latent form, 
do not produce viral proteins and peptides, and are for that reason not targeted by the immune 
system or ART [40]. Once ART is interrupted or during suboptimal treatment these 
transcriptionally silent, but replication-competent HIV-1 proviruses, are capable of resuming 
replication which results in rebound of viremia [41]. The latently infected  resting memory 
CD4+ T cell reservoir decays slowly; in fact, the half-life in chronically infected adults has been 
estimated to 40-44 months, indicating that ART would be required for more than 70 years for its 
eradication [38].  
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Different mechanisms contributing to the maintenance of the HIV-1 reservoir during ART have 
been suggested. There are studies suggesting a continued, low-level viral replication taking place 
during ART and upon integrase inhibitor intensification active replication is inhibited. In the 
presence of Raltegravir, which is an integrase inhibitor, integration of linear viral cDNA is 
blocked and DNA repair enzymes circularize the DNA to form episomes containing two copies 
of the viral long terminal repeat circles (2-LTR circles) [42, 43]. Another study showed how the 
stability of the reservoir is maintained via T cell survival through antigen-driven and 
homeostatic proliferation, suggesting that HIV-1 proviruses in infected cells can expand in the 
absence of viral replication [44]. Resting CD4+T cells are regarded as the largest reservoir and 
include different memory CD4+T cell subpopulations, with central memory (TCM), effector 
memory (TEM) and transitional memory (TTM) CD4+ T cells constituting a significant proportion 
of the reservoir [45-47]. Other cell types that have been proposed to contain HIV-1 DNA in 
latent form are macrophages and monocytes [48, 49]. Whether these cells are playing a role in 
maintaining the HIV-1 reservoir in patients on viral suppressive ART is still unclear.  
Studies on the HIV-1 reservoir have primary been performed using peripheral blood; these 
studies have the limitation that the virus reservoirs in resting memory T cells may mainly be 
present in lymphoid tissue and not be circulating in blood. The contribution of each subset might 
also vary when the subsets are sorted from tissues [41]. A number of other anatomical sites and 
tissue compartments have been proposed to act as reservoirs including the gastrointestinal (GI) 
tract and central nervous system (CNS). If these anatomical compartments are non-permissive to 
immune surveillance or have suboptimal drug-penetration viral replication may take place at 
these sites during ART. GALT is the biggest lymphoid tissue (LT)  in the body and studies have 
shown that it acts as a major tissue reservoir, where memory T cells with persistent HIV-
1infection are sequestered in infected individuals on effective ART [50, 51]. HIV-1 DNA has 
been detected in CNS resident macrophages in individuals on long-term suppressive therapy 
[52] and in lymph nodes where CD4+T cell populations are circulating. However, the 
contribution of these compartments to HIV-1 persistence has not yet been fully characterized 
and should therefore be thoroughly studies for the development of sufficient cure strategies.  
The reservoir in resting memory CD4+ T cells consists of a heterogeneous nature of proviruses 
that can be divided into two groups; induced proviruses and non-induced proviruses. Induced 
proviruses can release replication-competent virus after one round of T cell activation, whereas 
non-induced proviruses do not give rise to virions. Most non-induced proviruses are defective 
and a majority contains different inactivating defects. However, a small fraction of the non-
induced proviruses have fully intact genomes, termed intact- non-induced proviruses (INPs), 
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which can produce virions after additional rounds of cellular activation. Several assays quantify 
the HIV-1 reservoir, but none measures the true size; culture based assays detect only induced 
replication-competent proviruses, while PCR-based assays identify all types of proviruses but 
cannot separate between replication competent proviruses and defective proviruses [40] (Table 
1).  
The HIV-1 scientific community has recently turned its attention to the possibility of identifying 
novel targets for curing HIV-1 infection [53]. One possible strategy to eliminate HIV-1 cellular 
reservoirs is to induce replication of the latent HIV-1 genome; in presence of ART, the virus 
newly produced from latent reservoirs should be possibly eliminated before it infects new 
cellular targets.  Another strategy is to improve the immunological responses of HIV-1 infected 
patients with the hope that T-cell mediated immunity, especially CD8+ T cells, may be able to 
control virus infection once the patients are taken off ART. These are exciting possibilities.  
 
Table 1. Comparison of assays for measuring the HIV-1 latent reservoir. Adapted from [40]. 
Assay 
 
Detection 
method 
What it  
measures 
What it  
excludes 
Viral outgrowth 
assay (VOA) 
[37, 54, 55] 
p24 ELISA RT-PCR Replication-competent  virus Defective proviruses, INPs, 2-LTR circles  
qPCR for HIV-1 
DNA [56-58] 
 
qPCR Total proviral DNA   Proviruses with deletions in amplified regions 
qPCR for 2-LTR 
circles [42, 43] 
 
qPCR 2-LTR circles Integrated proviral DNA 
Cell-associated 
HIV-1 RNA [59] 
 
RT-qPCR Proviruses induced to make cell associated HIV-1 RNA Defective proviruses, INPs 
  
 
 
11 
 
2 ADAPTIVE IMMUNITY  
The adaptive immune system consists of humoral and cell-mediated immunity. One of the 
cardinal features of the adaptive immune system includes the generation of immunological 
memory. B cells mediate the humoral arm and convey their function by producing antibodies, 
which neutralize and eradicate extracellular microbes and toxins. T lymphocytes provide cell-
mediated immunity that eradicates intracellular microbes; T-cell mediated immunity includes T 
helper cells (Th; CD4+) which activate phagocytes to destroy ingested microbes and activate B 
lymphocytes to produce antibodies, and cytotoxic T lymphocytes (CTL; CD8+) that kill infected 
cells harboring microbes in the cytoplasm [56]. 
2.1 CD4+ and CD8+ T cells 
During a primary immune response, antigen-specific naïve T cells migrate to the T cell area of 
secondary lymphoid organs to scan for antigens presented by DCs. Naïve T cells that encounter 
the antigen undergo proliferative expansion and differentiate into effector cells. The activated 
effector T cells assist with the clearance of infection by migrating to the site of infection and 
orchestrating adaptive immune responses. After the clearance of the infection, the effector T 
cells will die and a fraction of primed T cells persists into various antigen-specific memory T 
cell subsets [56]. Memory T cells are divided into different subsets characterized by their 
phenotype and functional profiles. The main subsets of circulating memory T cells, TCM and TEM 
cells, can be distinguished by the expression of CCR7, a chemokine receptor homing to 
secondary lymphoid organs [57]. The TCM subset, which expresses the lymph node homing 
receptor CCR7, has the capacity to home to secondary lymphoid organs and to proliferate upon 
activation and an increased ability to survive. TEM cells, which are CCR7neg have direct effector 
functions after antigen stimulation [58]. After T cell receptor (TCR) triggering or, to a lesser 
extent, in response to homeostatic cytokines, such as IL-15 or IL-7, TCM cells can develop into 
TEM cells. [59].  
2.2 B cells 
Humoral immune responses can be initiated to either non-protein antigens or protein antigens, 
the latter including T cell-dependent (TD) responses. Naïve B cells in the lymphoid follicles 
bind to the protein antigen with specific immunoglobulin (Ig) receptors and are activated to 
migrate out of the follicles. Cognate CD4+ helper T cells, which already have been activated to 
differentiate into effector cells, interact with these antigen-stimulated B cells at the edges of 
lymphoid follicles. Helper T cells, through their T cell receptor, recognize peptide antigens 
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presented by B cells through their MHC class II molecules and activate B cells by expressing co-
stimulatory molecules and secreting cytokines. These signals together stimulate high levels of B 
cell proliferation and differentiation and induce heavy chain isotype switching [60].  The 
interactions of B and T cells, intensified by signals from follicular dendritic cells (FDCs), leads 
to the differentiation of T cells into follicular helper T (Tfh) cells [61].  Tfh cells are defined by 
follicular location and high expression of CXCR5, the T cell inhibitory receptor  programmed 
death 1(PD-1), and production of IL-21 [62]. Tfh cells in turn, drive B cell differentiation 
further, allowing them to proceed into a germinal center (GC) reaction where affinity maturation 
and the induction of somatic hyper mutation (SHM), is taking place. GCs are 
microenvironments that give rise to secondary B cell follicles [63]; GCs are usually formed a 
few days and up to a week after initiation of an immune response,  and persists for weeks or 
months depending on the antigen (Figure 4) [64].   
The ligand from the costimulatory molecule CD40 (CD40L) and the inducible costimulator 
(ICOS) have been shown to be required for TFH cells and GC development, whereas CXCR5 
and the adaptor SLAM associated protein (SAP) are important for TFH cells and GC reaction. In 
addition, CD40L, IL-21 and IL-4 play major roles in regulating GC B cell proliferation, survival 
and affinity maturation. B cells can also develop in their absence of these signals but their 
function is defective [62, 65].  Lack of IL-21R signaling on B cells is associated with lower 
levels of the transcription factor Bcl-6, resulting in reduced B cell proliferation  and switching to 
IgG1 in GCs [65]. 
Affinity maturation is giving rise to B cells with high affinity B cell receptors (BCRs) to bind the 
specific antigen, through a process where the affinity of antibodies for protein antigen increases 
with prolonged or repeated exposure to the antigens [66]. Heavy chain isotype switching may 
also occur throughout the GC reaction and not only before the formation of the GC [67]. The 
exit of B cells from the GC reaction gives rise to both long-lived plasma cells which home to the 
bone marrow (BM) [68] and memory B cells which are mainly preserved in secondary lymphoid 
organs with a proportion recirculating in the periphery [64].  
Marginal Zone (MZ) B cells belong to a subset of B cells found in the marginal zone of the 
spleen and act as innate-like lymphocytes able to initiate rapid antibody responses both to T-cell 
independent (TI) and TD antigens. MZ B cells express less specific BCRs and high levels of 
toll-like receptors (TLRs) which are binding to microbial molecules such as lipopolysaccharide 
(LPS) or polysaccharides.  
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The antigen binding to BCR and TLR molecules activate MZ B cells by having transmembrane 
activator and CAML interactor (TACI) binding to both a proliferation-inducing ligand (APRIL) 
and B cell activating factor (BAFF) released by neutrophils, macrophages and DCs. Neutrophils 
in the spleen release IL-21, which induces the expression of activation-induced cytidine 
deaminase (AID), class switching to IgA and IgG; antibody-secreting plasmablasts receive 
additional maturation and survival signals from CXCL10, IL-6 and type I IFNs produced by 
antigen-capturing cells through a TI-pathway (Figure 4) [69].   
Blood-borne bacteria also express TD antigens, like outer-membrane proteins which are 
processed to peptides and presented to CD4+ T cells through MHC class II. MZ B cells are 
better antigen-presenting cells (APCs) than follicular B cells, with increased levels of MHC 
class II, CD80 and CD86 and may participate in the activation of naïve T cells, at least in mice 
[69, 70]. For GC reaction to take place MZ-primed naïve CD4 T cells need to differentiate into 
Tfh cells, which thereafter stimulate antigen-specific B cells through a CD40-dependent 
pathway that leads to the expression of class-switched high affinity antibodies and long-lived 
memory B cells and plasma cells.  A subset of these Tfh cells also interact with extrafollicular 
MZ B cells and promotes the generation of low-affinity IgM and IgG [69].  
It is debated whether human IgD+IgM+CD27+B cells in the blood are generated from GC 
responses or in the splenic marginal zone independently of T-cell help [71]. Human 
IgD+IgM+CD27+B cells have been shown to share IgV gene mutations with GC-derived IgG 
memory B cells; it has been suggested that these cells are able to respond to TD-antigens 
although they leave the GC reaction before switching to other isotypes [72].  In addition, these 
cells have also been shown to be present in patients with either CD40 or CD40L deficiency, thus 
indicating that this subset, can at least in part be generated independently of T cell help [73]. 
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Figure 4.  Follicular B cells involved in T cell dependent immune responses involving GC 
reactions and the production of high affinity antibodies (A) and MZ  B cells that rapidly produce 
low affinity antibodies independently of T cells (B), adapted from [62, 69]. 
 
2.2.1 Co-stimulatory pathways regulating B cell responses 
Co-stimulatory molecules expressed as receptor and ligand pairs on B cells and T cells are 
regulating the survival of B cells and T cell-dependent B cell responses; these includes members 
of the tumor necrosis factor (TNF) and TNF receptor (TNFR) family, such as CD27/CD70  and 
the CD40/CD40L molecule pairs and BAFF binding to its three different receptors, BAFF 
receptor (BAFFR), B cell maturation antigen (BCMA) and TACI [74, 75].  The T/B cell 
crosstalk taking place through CD40L expressed on the surface of activated T cells engaging 
CD40 expressed by B cells is crucial for T cell dependent humoral immunity and gives rise to 
the initiation and progression of the GC reaction [76]. CD70 is expressed transiently on T cells, 
B cells or DCs during activation. The interaction between CD27, expressed on activated B cells 
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and CD70, when expressed on activated T cells, enhances Ig production by B cells, suggesting 
that the CD27/CD70 interaction is included in the differentiation of B cells into plasma cells [77, 
78].  BAFF is a crucial survival factor for peripheral B cells, and binds to three receptors on B 
cells; BAFFR is essential for survival and maturation of immature B cells, BCMA promotes 
plasma-cell survival while TACI is critical for T cell-independent antibody responses, class-
switch recombination and as negative regulator of the size of the B cell compartment. BAFF is 
mainly produced by innate immune cells such as macrophages, neutrophils, monocytes, DCs 
and FDCs but can also be produced by T cells and B cells [79].  Mice deficient in BAFF lack 
mature B cells and are immunodeficient [80],  while elevated expression of BAFF is associated 
with autoimmunity; BAFF is in fact a therapeutic target for the treatment of patients with 
systemic lupus erythematosus (SLE) [81].  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                      
2.3 Physiological role of molecules involved in HIV-1 pathogenesis 
and which will be discussed in the present thesis 
HLA-DR is one part of the MHC II molecule, with the other parts being HLA-DP and HLA-
DQ. The invariant HLA-DM molecule is involved in loading peptides onto MHC class II 
molecules while HLA-DO acts as a negative regulator of HLA-DM [82]. The MHC II molecules 
are highly expressed on APCs such as B cells, macrophages and DCs; through MHC II these 
cells present processed exogenous antigen to CD4+ T cells and regulate immune responses [83, 
84]. The expression of HLA-DR antigen can be up-regulated and down-regulated by different 
cytokines. T cells express HLA-DR upon activation, although with a slower kinetics when 
compared to professional APCs [84]. 
Human CD38 is a surface glycoprotein, initially designated merely as an activation antigen 
when first discovered in the 1980s. Today we know that this molecule can also behave as a cell 
surface enzyme (i.e., ectoenzyme) involved in transmembrane signaling, cell adhesion and 
influencing cell migratory responses [85, 86]. CD38 supports leukocyte trafficking between the 
blood and the tissues, by controlling the signals that are triggered by chemokine-receptor 
engagement [101]. CD38 is expressed by immature hematopoietic cells and at high levels by 
activated B- and T cells and natural killer (NK) cells [85].  
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CD28 is a co-stimulatory receptor expressed on T cells, involved in the activation of naïve T 
cells after the engagement of its ligands, B7-1 (CD80) or B7-2 (CD86) [87]. T cell activation 
includes two signals, first T cell receptor (TCR) recognition and binding to antigen presented on 
MHC II on the APC. The second signal includes the binding of the B7 ligand on the APC with 
CD28 on the T cell [88]. The two signals initiate T cell clonal expansion, cytokine secretion and 
effector functions. Blockade of CD28 signaling results in inefficient T cell activation and CD28 
is gradually down-regulated when central memory cells differentiate into effector cells [89].  
CD57 is a terminally sulfated glycan carbohydrate. CD57 expression increases with age, from 
absence in newborns to around 15-20% in adults and is frequently expressed on T cells in 
individuals with chronic immune activation [90]. CD57 expression on CD8+ T-lymphocytes 
identifies terminally differentiated cells with reduced proliferative responses to TCR triggering 
and the cytokines IL-2, IL-7 or IL-15, as well as increased sensitivity to antigen-induced 
apoptosis [91].  
PD-1and its ligands, PD-L1 and PD-L2 regulate the balance between T cell activation, tolerance 
and immunopathology. PD-1 is an inhibitory receptor expressed on activated T cells, B cells, 
NK T cells, activated monocytes and DCs. PD-L1 is constantly expressed on macrophages, T 
and B cells, DCs and BM-derived mast cells and is upregulated on different cell types after 
activation. PD-L2 is expressed on DCs, macrophages, and BM-derived mast cells [92]. HIV-1 
has found a way to use the PD-1: PD-L pathway to avoid immune responses and to maintain 
persistent infection; functional dysregulation of CD8+ T cells is a reason for an inefficient viral 
control during HIV-1 infection in humans [93, 94].  
The receptor for IL-7 is a heterodimer molecule composed of IL-7Rα and the γ-chain [95]. The 
α-chain of the IL-7 receptor is also named CD127. IL-7 is needed for T cell maturation, naïve 
and memory T cell survival and to stimulate T cell activation [96]. In the periphery, both naïve 
CD4+ and CD8+ T cells express high levels of IL-7Rα and TCR signaling downregulates its 
expression. TCM and TEM cells both express IL-7Rα, with the highest levels found on TCM cells. 
[95]. Persistent HIV-1 infection is associated with exhausted CD8+ T cells that express low 
levels of IL-7Rα and high levels of PD-1 [93], a phenotype which contrasts the CD8+ memory T 
cells that emerge following the clearance of an acute viral infection, characterized by high levels 
of expression of IL-7Rα and efficiently maintained for long term without antigen via IL-7 and 
IL-15 homeostatic self-renewal [97] The expression of IL-7Rα is considered to be a correlative 
marker of protective antiviral immunity, whereas lack of IL-7Rα expression appears to correlate 
with failed immunity [95]. 
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CD95, also known as Fas, is a transmembrane protein and a member of the TNF-R family. Its 
physiological ligand CD95L (FasL) is a member of the TNF cytokine family and together they 
are part of the extrinsic apoptotic pathway, mediating apoptosis with the main purposes of 
maintaining T-cell mediated immune responses and deleting autoreactive T cells [98]. CD95 is 
ubiquitously expressed on most cells, while CD95L is mainly expressed on activated T cells and 
NK cells [99]. Once the engagement of the death receptor CD95 by CD95L occurs, apoptosis 
will be triggered; to prevent killing of healthy cells the expression of CD95L is highly regulated 
[98]. A well established pro-apoptotic activity of CD95 is to mediate the apoptotic death of 
either cancer cells or virus-infected cells when triggered by CD95L on a CD8+ T cell [99]. 
 
3 HIV-1 PATHOGENESIS 
 
3.1 CD4+ T cell depletion  
The hallmark of HIV-1 infection is the massive depletion of CD4+ T cells. Although many 
treated HIV-1 infected individuals are able to fully suppress viral infection, ART fails to 
regenerate CD4+T cells to pre-infection levels [100, 101]; also low CD4+ T cell nadir has been 
shown to be a crucial factor in the inadequate immune recovery after ART [102]. In addition,  a 
study was showing that HIV-1 infected patients that maintain an abnormally low CD4+ T cell 
count despite many years of suppressive ART, had low levels of CD4 + TCM  and CD4+ TEM cell 
populations, with elevated levels of immune activation and high turnover rates, as compared 
with successful treated HIV-1 infected patients and non-infected subjects [103]. These findings 
argue for the importance of early ART initiation in HIV-1 infected patients, which would lead to 
an enhanced recovery of CD4+ T cells and improved long-term immune function in ART treated 
patients. 
CD4 + T cells can be characterized into Th1, Th2, Th17, Tfh and regulatory T helper cell (Treg) 
subsets based on location, function and cytokine profile (Table 2). 
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Table 2. Cytokine profile and functions of different subsets of CD4+ T helper cells 
 Location Function Cytokine profile 
Th1 Ubiquitous Intracellular infection IFN-γ 
Th2 Ubiquitous Humoral immunity 
against parasites 
IL-4, IL-5, IL-13 
Th17 Mucosa Mucosal immunity 
against parasites 
IL-17, IL-22 
Tfh LTs, GCs Humoral immunity IL-21 
Treg Ubiquitous Suppression of 
immune responses 
TGF-β, IL-10 
 
3.1.1 Alterations in T helper cell subsets 
Th17 cells are important for mucosal immunity and their massive depletion in the GALT in the 
first weeks of HIV-1 infection contributes to the impaired regulation of the epithelium and the 
breakdown of the mucosal barrier. In HIV-1 infected individuals, Th17 cell depletion correlates 
with chronic immune activation, microbial translocation, and disease progression [104, 105].  
The depletion of CD4+ Th17 cells in the gut results in a skewing of the fraction of CD4+ 
memory T cell subsets, from a Th17 to a Th1 phenotype [106]. Similar results have been shown 
in studies conducted in non human primates (NHP), with higher Th17 levels in mucosal tissues 
of healthy animals. In SIV-infected animals, the levels of Th17 cells decrease in the gut and are 
never restored, and as the infection progresses CD4+ Th1 cells become the main population 
[104, 106]. These results suggest that in HIV-1/SIV infection, Th17 regeneration is impaired, 
causing persistent defects in mucosal immunity.  
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CD4+ TCM cells are long-lived and self-renewing cells located in LNs and other LTs; these cells 
have limited effector functions but are able to proliferate in response to antigenic re-stimulation. 
CD4+ TCM maintain the homeostasis of CD4+ T cells by replacing non-self-renewing, short-
lived CD4+ TEM [59, 107]. The infection and depletion of the CD4+ TCM cells are, in comparison 
with the infection of CD4+ TEM cells, considered to contribute more significantly to the chronic 
immune activation since TCM are located in the lymph nodes, where immune responses are 
initiated, and their high levels of infection will therefore translate into high viral replication and 
activation [108].  
Tregs are phenotypically characterized as CD25hiCD127low and positive for the intracellular 
expression of Forkhead Box p3 (Foxp3) protein; they are regulating the effector activity of other 
immune cells through the secretion of cytokines like transforming growth factor (TGF)-β and 
IL-10 [109]. In HIV-1 infected individuals, the decreased levels of Th17 cells is giving rise to an 
increase in Tregs in the blood and GI tract, which has been shown to correlate with increased 
levels of activated CD8+T cells and plasma markers of microbial translocation [110]. The 
impact of Tregs during chronic immune activation is still debated; there are studies showing that 
decreasing Treg numbers and function will limit immune activation and booster HIV-1 specific 
immune responses [111, 112]. On the other hand, Tregs can act in a beneficial way, and by 
increasing their numbers and functions could possibly restrict chronic immune activation. This 
latter assumption is supported by a study [113], describing that both CD4+ and CD8+ T cell 
activation correlates with depletion of Treg numbers in HIV-1 infected individuals.  
There are studies showing that in viremic HIV-1/SIV infected subjects, the frequency of Tfh 
cells in LTs is either preserved or increased. The increase of Tfh cells in SIV-infected NHPs was 
shown to be associated with an increase in activated GC B cells [114, 115]. Interestingly, Tfh 
cells seem to be infected  at a similar frequency than  other CD4+ T cell subsets, indicating that 
the expansion of the Tfh cells is not due to a decreased susceptibility to HIV-1/SIV-infection 
[115-118]. These results suggests that during chronic HIV-1/SIV-infection, Tfh cells both 
expand in numbers and are infected at a high frequency contributing to HIV-1/SIV replication 
and production, but their role in maintenance of chronic immune activation in patients receiving 
ART still remains to be determined.  
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3.2 HIV-1 specific CD8+ T cell responses 
Following an acute infection, pathogen-specific T cells expand and differentiate into activated 
effector cells and, once the infection is cleared, develop into memory T cells which rapidly 
progress with effector functions and re-expand upon encountering the same pathogen [56]. 
During early HIV-1 infection, the first CD8+ T cell responses arise as viremia approaches its 
peak. During the time of the peak viremia, there is homogeneity of the founder virus indicating 
that at that time point no immune-driven selection of escape mutants is occuring. As viremia 
declines to the viral set point, following the peak of the CD8+ T cell response,  a rapid selection 
of mutations occurs in the virus genome [18]. As the infection progresses, the virus evades the 
CTL responses; this event contributes to the development of a chronic infection. During the 
infection, HIV-1 specific CD8+ T cells persists and become dysfunctional, a process commonly 
known as CD8+ T cell exhaustion [93, 119, 120]. 
3.2.1 T cell exhaustion 
Chronic infection, involving persistent exposure to antigen and inflammation, alters the memory 
T cell differentiation programme. Other factors contributing to T cell exhaustion are increased 
expression of  inhibitory receptors and lack of CD4 + T cell help [97]. Abnormalities linked to 
exhausted virus-specific CD8 T cells include the loss of IL-2 production and the high capacity to 
proliferate, followed by the loss of ability to produce TNF-α. As a consequence of severe CD8+ 
T cell exhaustion, HIV-1 specific cells partially or completely lose their ability to degranulate 
and to produce IFN-γ and a deletion of virus-specific T cells occurs [119]. During HIV-1 
infection, PD-1 is playing an important role in T cell exhaustion; an increased expression of PD-
1 on HIV-specific CD4+ and CD8+ T cells correlates with VL, lower CD4+ T cell count and the 
reduced capacity of CD8+ T cells to proliferate in response to HIV antigen in vitro [92, 93, 121].   
By comparing PD-1 expression on HIV-1 specific CD8+ T cells in long-term non-progressors 
(LTNPs) with typical progressors, it was shown that LTNPs express low levels of PD-1 on their 
HIV-1 specific CD8+ T cells; in contrast, the typical progressors presented with upregulated PD-
1 expression on CD8+ T cells which correlated with elevated VL, reduced CD4+ T cell number 
and decreased HIV-1 specific CD8+ TEM cells [92, 122].  
In addition to PD-1, other surface inhibitory molecules have been shown to be expressed on 
exhausted T cells and the severity of T cell exhaustion has been suggested to depend on the 
amount of inhibitory receptors expressed in one cell at the same time. There is a debate ongoing 
on whether the individual expression of PD-1 or other inhibitory receptors is a marker for 
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exhaustion, or if co-expression of multiple inhibitory receptors is a key feature of exhaustion 
[119]. Indeed, the high expression of many inhibitory receptors on CD8+T cells is associated 
with T cell exhaustion in HIV-1 infected individuals [123].   
The maintenance of exhausted T cells is also dependent on their transcription factors, such as 
Eomesedormin (Eomes) and T-box transcription factors (T-bet) and with their different levels of 
expression helping maintaining the pool of exhausted CD8+ T cells during chronic viral 
infection [124].  A recent study characterized the levels of EOMES and T-bet in CD8+ T cells 
from chronically HIV-1 infected, ART treated patients and found that HIV-1 specific CD8+ T 
cells expressed elevated levels of Eomes and low levels of T-bet, a profile associated with 
increased expression of inhibitory receptors, dysfunctional features and a transitional memory 
phenotype; this impaired profile was not normalized despite viral suppression with ART [120].  
3.2.2 T cell senescence 
T cell senescence is characterized by an expanded population of terminally differentiated  CD8+ 
T cells with shortened telomeres, increased expression of CD57 and down-regulation of the co-
stimulatory molecule CD28 [89, 125]. A recent study [126], showed increased levels of immune 
activation, measured by the increased soluble CD14 (sCD14) levels in plasma and higher 
percentages of CD38+ HLA-DR+ CD4+ and CD8+ T cells, in HIV-1 infected ART treated 
patients compared with controls; the CD4+ T-cell activation in the treated HIV-1 infected 
patients was inversely associated with CD4+ T-cell count and CD4+ T-cell recovery. 
Interestingly, increased immune activation was also associated with shorter telomeres, 
suggesting that chronic inflammation associated with HIV-1 disease drives excess activation and 
proliferation of T cells, which in turn leads to telomere shortening and ultimately to poor 
immune recovery and the immune-senescent phenotype. Another study found that the 
immunosenescent phenotype of CD28- CD8+T cells was evident already within the first few 
months of infection and reversed by early initiation of ART, but not when ART was delayed by 
a few years, illustrating the relevance of early initiation of ART [127]. However, our group 
showed earlier that only CD28- T cells from non-treated HIV-1 infected patients were associated 
with an immunosenescent phenotype while CD28- T cells isolated from ART-treated HIV-1 
infected patients, were more prone to proliferation as compared to cells from non-treated HIV-1 
infected and non-infected individuals [128]. 
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3.3 Chronic immune activation 
The driving force for CD4+ T cell depletion and the development of AIDS is the systemic 
chronic immune activation taking place in HIV-1 infected individuals [129]. Although ART can 
almost completely suppress HIV-1 replication, prevent AIDS and reduce mortality, antiviral 
drugs are not completely targeting immune activation and several years of viral suppression, 
residual immune activation persists [129-131]. New recent findings indicate that the suppression 
of viral replication by ART is incomplete in almost all treated patients [43, 132], suggesting that 
the levels of activated CD4+ T cells in patients receiving ART may contribute to HIV-1 
persistence by constantly providing a pool of cellular targets for virus infection [133].   
Treated HIV-1 infected adults, as compared to age-matched uninfected individuals, are at a 
higher risk of developing non-AIDS related diseases, including cancer, liver, kidney, 
cardiovascular, neurologic and bone diseases [31, 134]. Immune activation, chronic immune 
dysfunction and inflammation most probably contribute to the increased risk of morbidity and 
mortality in HIV-1 infected individuals. A few factors have been shown to contribute to the 
immune dysfunction and persistent inflammation in HIV-1 infected individuals undergoing 
treatment; (I) untreated HIV-1 infection gives rise to collagen deposition in lymphoid organs, 
causing irreversible tissue fibrosis, which is not normalized once treatment is initiated and 
contributes to failed T-cell homeostasis [135, 136];  (II) destruction of mucosal surfaces within 
the gut, giving rise to microbial translocation [137]; (III) increased replication of common 
pathogens such as cytomegalovirus (CMV) [138] and (IV) persistent inflammation [133] (Figure 
5).  
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Figure 5. Factors contributing to chronic immune activation in ART- treated HIV-1 infected 
individuals. Adopted from [129]. 
 
3.3.1 HIV-1 induced collagen deposition in secondary LTs 
HIV-1 replication occurs mainly in the secondary LTs and as the infection progresses, the high 
endothelial venules (HEVs) become thickened and sclerotic, giving rise to accumulated collagen 
throughout the T cell zone. Tregs produce transforming growth factor (TGF)-β1, which 
stimulate fibroblasts to produce and deposit collagen during the course of infection. The 
deposited collagen damages the fibroblastic reticular cell (FRC) network, leading to a reduced 
availability of IL-7 which results in loss of naïve T cells and an increased apoptosis in both 
CD8+ and CD4+ T cell subsets. For maintaining the FRC network, it physically needs to interact 
with T cells to receive lymphotoxin signals, which are produced by CD4+ T cells. The FCR 
network loss is mainly caused by the CD4+ T cell depletion in parallel with collagen deposition 
leading to the loss of interaction between CD4+ T cells and  the FRC network This pathological 
mechanism is initiated in the early infection, and therefore, initiating ART during PHI correlates 
with  improved  preservation of CD4+ T cells and lower apoptosis of naïve T cells in LTs [136]. 
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3.3.2 Microbial translocation 
Th17 cells are massively depleted in GI tract within the first weeks of infection; contributing to 
the disruption of tight junctions, loss of intestinal epithelial cells and weakened mucosal 
intestinal barrier. The compromised mucosal immunity in the gut is favoring translocation of 
bacterial and fungal products, such as flagellin, LPS, peptidoglycan and ribosomal DNA, from 
the lumen to the systemic circulation. These microbial products, through the stimulation of 
several TLRs, generate different pro-inflammatory cytokines, such as IL-6, IL-1β,TNF-α and 
type 1 Interferons in different immune cells contributing to the aberrant immune responses 
during chronic HIV-1 infection [133].  
Increased LPS levels in circulation have been described in relation to microbial translocation 
during chronic HIV-1 infection [139]. LPS makes up the layer of the outer membranes of most 
gram-negative bacteria and works as an activator of the innate immune system through TLR4 
[140]. In studies of Sooty mangabey monkeys that represent natural hosts for SIV-infection and 
do not develop HIV-1 associated disease, immune activation is not occurring and low levels of 
LPS are found in plasma and in the colon [137, 141]. In another study, designed to decrease 
microbial translocation, acutely SIV-infected macaques were treated with an antibiotic and an 
anti-inflammatory drug; the treatment reduced LPS levels in plasma, and transiently decreased  
the levels of immune activation and viral replication in treated SIV-infected macaques as 
compared with non-treated SIV-infected animals [142].  
3.3.3 Reactivated infections which may increase immune activation 
HIV-1infected individuals are more often present with other chronic viral infections; different 
latent viruses, such as herpex simplex virus (HSV),  cytomegalovirus (CMV) and Epstein-Barr 
virus (EBV) are due to CD4+ T cell depletion more often reactivated in HIV-1 infected 
individuals [129]. A few studies have pointed out a role for opportunistic viruses in maintaining 
chronic immune activation during HIV-1 infection; the activation marker CD38 was shown to be 
upregulated on CD8+ T cells specific for, EBV, CMV and influenza virus, as well as on HIV-1 
specific CD8+ T cells during primary HIV-1 infection [143]. A recent clinical study showed that 
treatment of HIV-1 infected individuals with an antiviral drug used to treat CMV infection, 
significantly decresed the levels of HLA-DR+CD38+ CD8+ T cells in ART treated HIV-1 
infected individuals with low CD4+ T cell count, further proving evidence that CMV (or/ and 
other herpesvirus) replication may affect  immune activation during HIV-1 infection [138]. 
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3.3.4 Markers of immune activation during HIV-1 infection 
HIV-1 infected individuals are usually observed with increased levels of the activation markers 
HLA-DR and CD38 and Ki-67, the marker for proliferation on both CD4+ and CD8+ T cells 
[144].  Immune activation is also characterized through the measurement of plasma biomarkers 
of inflammation, such as C-reactive protein (CRP), TNF-α, IFN-γ, IL-6 , β2-microglobulin 
(β2M) and the coagulation cascade marker, D-dimer, which are all increased in chronic HIV-1 
infection [145-147]. In chronic HIV-1 infection, the levels of the anti-inflammatory cytokines 
TGF-β and IL-10 are elevated but also predictable of progression to AIDS [148].  β2M is a 
component of the MHC I complex, released by activated T cells and elevated during HIV-1 
infection, which levels inversely correlated with CD4+ T cell counts [146]. In the acute phase of 
infection, levels of the marker IFN-inducible protein-10 (IP-10) in plasma have been shown to 
be predictive of rapid disease progression [149] and sCD14, the marker of monocyte activation 
released in response to LPS and an indirect marker of microbial translocation has been shown to 
negatively correlate to CD4 T cell counts in treated HIV-1 infected individuals [126].   
 
3.4 B cell dysfunction during HIV-1 infection 
HIV-1 infection is in addition to the depletion and dysfunction of CD4+ T cells also associated 
with activation and dysregulation of B cells. In the early course of  infection, HIV-1 replication 
is driving the immune activation leading to bystander pathological effects on B cells [150]. B 
cell alterations include loss of serological memory to antigens previously encountered through 
vaccination and natural infection [151-155]. 
3.4.1 Direct and indirect effects of HIV-1 viremia on B cells 
It has not been shown that HIV-1 can efficiently replicate in B cells as these cells lack the 
expression of the CD4 molecule, the main receptor for HIV-1. Studies have however showed 
that there is a direct interplay between the virus and B cells in vivo, through the interaction of  
HIV-1 virions bound to complement proteins and CD21, the complement receptor expressed on 
mature B cells [156, 157]. In addition to CD21, other HIV-1 binding receptors have been 
described on B cells, such as DC-SIGN and other C-type lectin receptors, but their role as HIV-1 
receptors in vivo is unknown [158, 159]. A recent study identified gp120 binding to human B 
cells via integrin α4β7, contributing directly to B cell dysfunction by activating inhibitory 
pathways resulting in the increased expression of the immunosuppressive cytokine TGF-β1 and 
the inhibitory receptor FcRL4 [160]. The frequency of B cells with HIV-1 virions on their 
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surface is relatively low in comparison to the degree of B cell dysfunctions taking place in HIV-
1 viremic individuals, indicating that B cell damage is occurring through indirect mechanisms 
during HIV-1 infection. 
HIV-1 induced aberrant immune activation is giving rise to B cell hyperactivation and 
hypergammaglobulinemia, the latter phenomenon characterized by increased levels of 
immunoglobulin in the circulation. Other features of hyperactivation include increased B cell 
turnover and increased B cell malignancy [151, 161, 162].  The HIV-1 protein Nef appears to 
affect B cells in multiple ways; infected macrophages that express Nef generated the protein 
ferritin, which induced B cell activation in HIV-1 infected individuals and IgG levels in the 
serum correlated with ferritin and VL [163]. In addition, Nef has also been shown to compile on 
B cells and to prevent Ig class-switch DNA recombination by blocking CD40 ligand signaling 
pathway [164].  
3.4.2 Alterations in B-cell subsets  
The B cell abnormalities induced by HIV-1 are not the result of the appearance of new B cell 
subsets absent in healthy individuals, but rather originate from an imbalanced frequency of B 
cell subsets present in healthy individuals [150]. An increased frequency of immature 
transitional (CD19+ CD10+) B cells are present in the blood of HIV-1 infected individuals [165, 
166], results from the increased levels of transitional B cells (CD19+CD10+CD21+CD27-) and 
GC founder B cells (CD19+CD10+ CD21+CD27+) [167]. Transitional B cells respond weakly 
to BCR stimulation and are more sensitive to spontaneous apoptosis [165]. The pathogenic 
mechanisms that give rise to the increased levels of transitional B cells in the blood during   
HIV-1 infection are not fully known but the cytokine IL-7, which is increased during untreated 
HIV-1 infection, has been shown to influence the ratio of transitional B cells; in fact, the 
increased levels of immature/transitional B cells are more evident in advanced HIV-1 disease 
and correlate with increased IL-7 levels [165, 168].  
In HIV-1 infected individuals, the frequency of resting memory (RM) B cells (CD19+ CD10- 
CD27+CD21+) is decreased [153, 161, 169], and correlates with the reduced levels of antibodies 
against different vaccination antigens (tetanus, pneumococcus and measles) [153, 170]; the 
decreased maintenance of serological memory has been shown to take place early during HIV-1 
infection [171].  
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A common pathogenic feature for B cells from viremic HIV-1 infected individuals is the over-
representation of memory B cells that express low levels of CD21, namely activated memory 
(AM) B cells (CD19+ CD10-CD27+CD21-), which express the highest levels of activation 
markers CD80 and CD95 and respond weakly to different B cell stimuli among all B cell subsets 
[151], and tissue-like memory (TLM) B cells (CD19+CD10-CD27-CD21-) which express the 
inhibitory receptor FcRL4 and display an exhausted phenotype, including lower epitope 
diversity, lower capacity to proliferate and a reduced number of cell divisions [172]. Silencing of 
the inhibitory receptor FcRL4 and Siglec-6 on B cells resulted in increased B cell proliferation 
and cytokine release in viremic HIV-1 infected patients, confirming the presence of B cell 
exhaustion during HIV-1 infection [173]. The characteristic exhausted phenotype of TLM B 
cells include the expression of PD-1, the inhibitory receptor associated with exhausted T cells 
during HIV-1 infection [93]. In a recent study, PD-1 expression was measured on all memory B 
cell subsets of HIV-1 viremic individuals, and it was shown that PD-1 expression was elevated 
only on RM B cells; suggesting that increased expression of PD-1 might be associated with the 
reduced number of this subset of B cells in HIV-1 infected individuals [174].   
The decreased survival of memory B cells in HIV-1 infection has been suggested to be affected 
by the death receptor-mediated pathway; in fact, viremic and lymphopenic patients has been 
shown to upregulate CD95 on their memory B cells as compared to healthy controls [174]. In 
addition, the increased frequency of AM B cells sensitive to CD95-mediated apoptosis 
correlated with viremia [175]. 
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Table 3. Identification of memory T and B cells in the thesis is based on expression of CD45RA 
and CCR7 on CD3+CD4+/CD8+ T cells and CD27 and CD21 on CD19+CD10- B cells. 
 
Naive  
    T 
cells 
 
Central 
memory 
T cells 
(TCM) 
 
Effector 
memory 
T cells 
(TEM) 
 
CD45RA+ 
effector 
memory 
T cells 
(TEMRA) 
 
Naive 
B cells 
 
Resting 
memory  
B cells 
(RM) 
 
Activated 
memory 
B cells 
(AM) 
 
Tissue-like 
memory  
B cells 
(TLM) 
 
CD45RA + - - +     
CCR7 + + - -     
CD21     + + - - 
CD27     - + + - 
 
3.4.3 Reduction of HIV-1 viremia by ART leads to normalization of some B cell 
dysfunction 
During ART, normalization of the frequency of some B cell subsets has been shown to be slow 
and incomplete. After one year of treatment, the frequencies of AM and TLM B cells had not 
normalized, suggesting that despite suppression of viremia induced by ART, some immune-
activating effects of HIV-1 persist [167, 176]. Hypergammaglobulinemia, which is maintained 
at elevated levels during chronic viremia is not completely normalized after ART initiation [153, 
161]. In addition, HIV-1 infected individuals initiating ART in the chronic phase of infection are 
not able to restore the RM B cell compartment [152, 176]. However, initiating ART during PHI 
is associated with improved B cell memory function as measured by improved B cell memory 
response to a recall antigen in both adults and children [167, 170]. 
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4 AIMS OF THE THESIS 
 
 The specific aims of this thesis are: 
 
- Study the impact of microbial translocation and immune activation on dysfunctions of B 
cells in HIV-1 infected patients (paper I). 
 
- Investigate the role of IL-7 on B cell survival and activation, and antibody production 
(paper II). 
 
- Study the role of altered CD70 expression on T cells to B cell abnormalities during HIV-1 
infection (paper III). 
 
- Investigate whether ART initiated during primary HIV-1 infection prevents the 
establishment of abnormal phenotypic features of CD4+ and CD8+ T cells (paper IV). 
 
- Investigate whether ART initiated during primary HIV-1 infection leads to a preserved B 
cell compartment (preliminary results). 
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5 RESULTS AND DISCUSSION 
 
5.1 PAPER I - Impact of microbial translocation and immune 
activation on B cell activation and loss of memory B cells in   
HIV-1 infected patients 
Memory B cells are, in addition to plasma cells, the cellular component responsible for the 
maintenance of serological response to antigens previously encountered in life through natural 
infection and vaccination. In the context of  HIV-1 infection, different B cell alterations occur 
including a decline in the frequency  of resting memory B cells in both adults and children and 
loss of serological memory [152, 154] . 
Microbial translocation and abnormal immune activation were shown to be involved in 
impairment of T cell function and disease progression during HIV-1 infection [137];  however, 
as T cells, also B cells present with activation and exhaustion features [151, 172].  Therefore, we 
were interested in studying the impact of HIV-1 replication and microbial translocation on 
frequency of B cells and loss of memory B cells.  
     
A B
 
Figure 6. B cell phenotype during HIV-1 infection. Representative plots on the gating strategy of B cell 
subpopulations gated on live CD19+CD10- B cells (A). Frequency of total B cells (CD19+), naïve B cells 
(CD19+CD10-CD27-CD21+), classical memory B cells (CD19+CD10-CD27+), resting memory (RM) B cells 
(CD19+CD10-CD27+CD21+), activated memory (AM) B cells (CD19+CD10-CD27+CD21-) and tissue-like 
memory (TLM) B cells (CD19+CD10-CD27-CD21-) (B). 
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The frequency of B cell sub-populations during HIV-1 infection is shown in Figure 6. As 
compared to non-infected individuals, untreated HIV-1 infected patients exhibited a decrease of 
naïve B cells, whereas transitional B cells (CD19+CD10+) were expanded as shown in Figure 
6A. As anticipated, the frequency of resting memory (RM) (CD19+CD10-CD27+CD21+) B 
cells was decreased in HIV-1 infected individuals while activated AM (CD19+CD10-
CD27+CD21-) and TLM (CD19+CD10-CD27-CD21-) B cells were found at higher frequency. 
These results confirm previous studies which found a larger frequency of activated and 
exhausted B cell cells in the circulation of viremic HIV-1 infected individuals [151, 172]. 
Following initiation of ART, these alterations are reversed except for the decreased population 
of RM B cells which is also found in ART treated patients. The abnormal distribution of B cell 
subsets which we found in HIV-1 infected patients has also been reported in other studies [172, 
177].  
IL-21R, the receptor for IL-21, has been shown to be upregulated upon B cell activation and to 
play a role in B cell differentiation and survival [178]; we therefore measured the IL-21R 
expression on B cells from control subjects and patients (Figure 7A). In general, both in 
uninfected controls and HIV-1 infected individual, IL-21R expression is high on naïve B cells, 
AM and TLM cells, the latter finding consistent with their activation status; on the other hand, 
classical memory and RM B cells display a moderate expression of this receptor. An increased 
level of IL-21R expression was found on classical memory (CD19+CD10+CD27+) B cells and 
TLM B cells of viremic HIV-1 infected patients.  
We also measured the expression of CD38, a known marker of immune activation. Higher levels 
of CD38 expression were shown on total B and classical memory B cells from viremic patients, 
as compared to ART-treated and uninfected individuals. In paper I, CD38 expression on all B 
cell subsets was inversely correlated with CD4+ T cell counts and correlated with HIV-1 VL for 
all subsets, except RM and TLM B cells. These results suggest a role for HIV-1 replication, and 
possibly lymphopenia, on the upregulation of CD38 on B cells from viremic patients (results 
shown as supplementary Figure 3 in Paper I). No correlation was however found between IL-
21R expression on B cells and CD4+ T cell counts or HIV-1 VL. 
We further explored the association of IL-21R expression with loss of memory B cells during 
HIV-1 infection (Figure 7B). We found an inverse correlation between the levels of IL-21R 
expression in both classical memory B cells and RM B cells and the frequency of these cells in 
circulation of treated and untreated HIV-1 infected individuals. Of note, no correlation was 
 
 
32 
 
found between the CD38 expression on memory B cells and the levels of these cells in 
circulation for any of the cohorts. Moreover, IL-21R+ memory B cells were more susceptible to 
apoptosis than memory B cells lacking the receptor, as shown by the lower expression of the 
anti-apoptotic molecule Bcl-2 and higher expression of Annexin V.  
A B
Figure 7.  IL-21R expression on memory B cell subpopulations and its correlation with reduced 
percentages of memory B cells during HIV-1 infection.  Frequency of IL-21R positive cells among 
total, naïve, classical memory, resting memory (RM), activated memory (AM) and tissue-like memory 
(TLM) B cells (A). Correlation of IL-21R expression with CD27+ classical memory (upper panel) and 
RM B cells (lower panel) in control subjects and HIV-1 infected patients (B). 
 
To determine whether microbial translocation could play a role in the establishment of B cell 
defects during HIV-1 infection, we measured the plasma levels of sCD14 (Figure 8A). The 
sCD14 levels were higher in HIV-1 infected patients, both viremic and treated, as compared 
with uninfected controls. To evaluate the impact of immune activation mediated by products of 
microbial translocation, in modulating IL-21R and CD38 expression on B cells, we correlated 
the levels of sCD14 with the frequency of different B cell memory subsets and expression of 
activation markers on these cells. A positive correlation was found between the sCD14 levels 
and the percentage of AM B cells whereas an inversely correlation was found between the 
sCD14 levels and RM B cells (Figure 8B).  These results suggest that microbial translocation 
may have a role in the expansion of AM B cells during HIV-1 infection, whereas microbial 
translocation has a negative impact on the frequency of RM B cells. The expression of IL-21R in 
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classical and RM B cells correlated with sCD14 levels, whereas CD38 expression in classical 
and AM B cells correlated with sCD14 levels. 
 
A B
 
Figure 8.  Plasma sCD14 correlates with both activation and loss of memory B cells.  Levels of 
sCD14 were measured by ELISA in plasma samples from uninfected control subjects and HIV-1 infected 
patients (A). The percentages of circulating classical memory (CD27+) B cells, activated memory (AM) 
and resting memory (RM) B cells and their respective levels of IL-21R and CD38 expression were 
correlated with the plasma levels of sCD14. These correlations were made including all groups (B). 
 
 
We also aimed at clarifying whether products of microbial translocation have a direct effect on 
IL-21 and CD38 expression on B cells. For this purpose we incubated separated B cells or 
PBMCs with different TLR ligands. Purified B cells or B cells in peripheral blood mononuclear 
cells (PBMCs) up-regulated IL-21R on both naïve and memory B cell subsets when stimulated 
with TLR-9 and TLR-2 ligands and, to a lesser extent, with TLR-4 ligands. CD38 expression 
remained unchanged when purified B cells were triggered by TLR ligands; however, CD38 was 
up-regulated on B cells in PBMC cultures in presence of TLR-3, TLR-4, TLR-7/8 and TLR- 9 
ligands. These results reveal a direct effect of TLR triggering on increased IL-21R expression on 
B cells, but not on CD38 expression, the latter depending on other cellular components present 
in PBMCs.  
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Abnormal immune activation is a well-studied feature of T cell immunopathology during HIV-1 
infection, which has been characterized through a variety of different surface markers. Very few 
studies have previously addressed the modulation of IL-21R and CD38 expression on B cells 
during HIV-1 infection. Chong and co-authors also reported that an elevated expression of 
CD38 on B cells can be found during untreated HIV-1 infection as a result of viremia [179]. In 
paper III we also studied the expression of CD38 on B cells in different cohorts of HIV-1 
infected patients, including patients presenting with viremia and lymphopenia. CD38 expression 
on B cells was increased in treated patients who maintained a low CD4+ T cell count (< 200/µl) 
in spite of ART and non-treated viremic patients, as compared to ART treated patients with 
CD4+ T cell counts >200/µl and healthy controls. 
Microbial translocation, resulting from the damaged epithelium barrier in the gut of HIV-1 
infected patients, has also been, in many contexts, associated with T cell decline and impairment 
of T cell phenotypes and function. This has become a central accepted knowledge in the field of 
HIV-1 pathogenesis. In paper I of my thesis it was shown that microbial translocation may also 
play a role in impairment of the B cell phenotype described to occur in HIV-1 infected patients. 
Increased levels of sCD14, is associated with both high IL-21R expression on memory B cells, 
which are more susceptible to apoptosis, and with reduced frequency of these cells in HIV-1 
infected individuals. 
It would be important to define a panel of markers defining abnormal activation of B cells 
during HIV-1 infection as these markers may be proven useful to define immune reconstitution 
and preservation upon early ART intervention.  
 
5.2 PAPER II - Role of IL-7 on B cell activation and survival  
 
Prior to ART introduction, increased levels of IL-7 in serum have often been associated with 
CD4+ T cell depletion in HIV-1 infected individuals [168]; this finding suggested that T cell 
depletion leads to high IL-7 levels, which, in turn, may lead to T cell regeneration through 
increased survival and proliferation.  In clinical studies in HIV-1 infected patients, IL-7 has been 
shown to positively affect T cell biology during HIV-1 infection, by enhancing the survival and 
expansion of T cells in HIV-1 infected individuals [180, 181].   IL-7,  however, appears  also to 
have a detrimental effect on B cells, as high IL-7 levels were associated with an increased ratio 
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of immature transitional B cells in the blood of HIV-1 infected individuals during CD4+ T 
lymphocytopenia, as well as during IL-7 therapy [165, 182]. 
Although peripheral B cells do not express IL-7Rα, an indirect role for IL-7 in influencing the 
biology of mature B cells has been shown. IL-7 treated T cells produce IFN-γ which, in turn, 
induces the upregulation of CD95 on B cells; through this mechanism, the sensitivity of B cells 
to CD95 mediated apoptosis increases [183]. In paper II, we further describe the role of IL-7 in 
regulating B cell activation and survival through mechanisms which involves activation of T 
cells and production of B cell survival factors from T cells. 
B cells co-cultured with T cells pre-treated with IL-7 for 5 days produced measurable levels of 
IgM and IgG, which were slightly higher than the levels found in cultures of B cells cultured in 
presence or absence of IL-7, or co-cultured with T cells without IL-7 (Figure 9A). This effect 
was more pronounced after 10 days of co-culture of B cells with IL-7 treated T cells; IL-7 
treated T cells induced the secretion of IgM, IgG and IgA similar to the levels detected upon 
CD40L stimulation (paper II).  
 
                      
A B
 
Figure 9. Immunoglobulin production and survival of peripheral B cells in the presence of IL-7 
treated T cells. B cells were cultured for 5 or 10 days, alone or with IL-7, or co-cultured with T cells 
treated or not with IL-7. Immunoglobulin concentrations were measured in culture supernatants by 
ELISA (A) and B cell survival was analyzed using Annexin V staining (B). 
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B cells cultured alone, or in the presence of IL-7, usually die after 5 days. The presence of T 
cells in culture, however, increased the survival of B cells; in addition, B cells in co-culture with 
IL-7 treated T cells displayed further enhanced viability. This additional effect of IL-7 was lost 
at day 10, with equal effect on B cell survival in presence of IL-7 pre-treated or non-treated T 
cells (Figure 9B). 
Next we studied the phenotype and proliferative capability of B cells co-cultured with IL-7 
treated or non-treated T cells. In co-culture with IL-7 treated T cells, B-cell proliferation was 
detected. These proliferating B cells down-regulated CD20 and expressed higher CD38 levels, 
characteristic features of activated plasmablasts. CD20-CD38+ B cells were significantly 
increased in cultures with IL-7 pre-treated T cells. These results demonstrated that IL-7 
treatment induces changes in T cells, which in turn enhance B cell activation and differentiation 
toward a plasmablast phenotype. Accordingly we searched for the molecular mechanism behind 
this finding.  
There are different co-stimulatory pathways involved in B cell activation during an immune 
response. CD27, a member of the TNFR family, is a marker of memory B cells and an important 
receptor for T-dependent B cell responses [184]. CD27 triggering by its ligand, CD70, is 
involved in B cell differentiation toward plasma cell and Ig secretion. CD70 was upregulated on 
T cells in the presence of IL-7, as shown in Figure 10A.  
BAFF is an important molecule for survival of B cells [74]. IL-7 induced BAFF production by T 
cells, as measured by ELISA (Figure 10B). In order to evaluate the role of BAFF on IL-7 
induced B cell survival, we blocked BAFF using a soluble BAFFR in cultures of B cells and IL-
7 pre-treated T cells. BAFF neutralization strongly decreased the effect of IL-7 treated T cells on 
B cell survival (Figure 10C), indicating that IL-7 promotes B cell survival via the induction of 
BAFF from T cells. 
We compared the effects of CD70 and BAFF neutralization on antibody production using the 
cultures of B cells and IL-7 pre-treated T cells described above. CD70 neutralization induced a 
significant reduction of IgG production both in the presence and absence of BAFFR. On the 
contrary, the presence of BAFFR in the B-T co-cultures did not affect IgG production. In 
addition, the effect of anti-CD70 blocking antibody was not enhanced by the presence of 
BAFFR (Figure 10D). A comparable effect of CD70 blocking was seen for IgM production. 
Taken together, these results indicate that IL-7 regulates B cell activation and survival via two 
distinct mechanisms, by inducing CD70 up-regulation and BAFF production in T cells. 
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Figure 10. Contribution of CD70 expression and BAFF production from IL-7 treated T cells to B 
cell activation and survival.  Percentage of CD70+ T cells among freshly isolated T cells (black dots) or 
T cells cultured in the presence (white dots) or absence (grey dots) of IL-7 for 5 or 8 days (A). BAFF 
concentration measured in the supernatant of T cells in the presence (white dots) or absence (grey dots) of 
IL-7 (B). Representative FACS plot is shown for B cells stained with Vivid and Annexin V after culture 
for 5 days alone, with untreated T cells, IL-7 treated T cells or with IL-7 treated T cells and recombinant 
BAFFR (C). B cells were cultured alone, in the presence of IL-7, untreated T cells or IL-7 treated T cells 
for 5 days and the levels of IgG antibodies were measured in the supernatants. The contribution of CD70 
and BAFF in the activation of B cells was studied using CD70 neutralizing antibodies (CD70) and 
soluble BAFFR respectively in the presence of IL-7 treated T cells (D). 
 
These results assign a functional role to CD70 expressed on T cells in inducing increased IgG 
production. Prior to ART it was clearly shown that T cells from HIV-1 infected patients have an 
increased CD70 expression [185]. Our group, and an additional paper published the same year, 
previously reported that CD70, ligand for CD27 molecule expressed on memory B cells, led to 
an increased IgG production and loss of memory B cells in HIV-1 infected patients [169, 186]. It 
is a well-known phenomenon that increased IgG level can be found in the serum of HIV-1 
infected patients not receiving treatment. The mechanisms underlying B-cell polyclonal 
activation and hypergammaglobulinemia during HIV-1 infection remain poorly understood and 
the contribution of increased CD70 expression on T cells to this phenomenon promoted the 
following study, denominated as paper III. 
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5.3 PAPER III - Altered CD70 expression on T cells and its potential 
contribution to B cell abnormalities during HIV-1 infection 
 
In paper II, we could show that CD70 molecules expressed by CD4+ T cells stimulate memory 
B-cell activation and antibody production in a non-antigen specific manner in vitro. In the 
context of HIV-1 infection, such mechanisms might theoretically be implicated in B cell 
activation and the increased IgG production, which is named as hypergammaglobulinemia, 
detected in patients. To clarify the involvement of these molecules in B cell activation during 
HIV-1 infection, CD70 expression on T cells and the functional and migratory properties of the 
CD4+CD70+ T cells were analyzed in paper III, in the following cohorts of HIV-1 infected 
individuals matched for age and gender and non-infected controls: 
1) 20 HIV-1-infected patients naive to ART with CD4+ T-cell counts higher than 350 
cells/µl (mean = 600 ± 271 cells/µl) and viral load ranging between 200 and 132 000 
(median = 21 500) copies/ml. This group is defined as 
2) 25 patients receiving ART and characterized by undetectable viraemia (<25 copies/ml) 
and CD4+ T-cell counts higher than 200 cells/µl (mean = 497 ± 222 cells/µl). This group 
is defined as 
viremic. 
3) 10 ART-treated CD4+ T-cell lymphopenic patients, with CD4+ T-cell counts below 200 
cells/µl for a period of 3–20 years. Viral load ranged in these patients between 
undetectable and low (<100 copies/ml) levels, mean CD4+ T-cell count was 145 ± 65 
cells/µl. This group is defined as 
non-lymphopenic, non-viremic.  
lymphopenic
4) 10 non-infected 
. 
controls
 
 matched for age and gender to the HIV-1 infected cohorts.  
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Figure 11. CD70 expression on CD4+ T cells in HIV-1 infected and non-infected individuals in 
relation to CD4+ T cell counts and viremia. CD70 expression was analyzed, using flow cytometry, on 
CD4+ T cells (A) of non-infected individuals (ctrl) and HIV-1 infected patients. The correlation is shown 
between CD4+ T cell counts in HIV-1 infected individuals and prevalence of CD70+ cells among all 
circulating CD4+ T cells (B). The frequency of CD4+CD70+ T cells correlates with VL in viremic HIV-
1-infected patients (C).  
 
 
We detected a significantly increased frequency of CD4+CD70+ T cells in lymphopenic patients 
as compared to non-infected individuals (Figure 11A). An inverse correlation was observed 
between CD4+ T cell counts and the frequency of CD4+CD70+ T cells in the whole group of 
HIV-1 infected patients (Figure 11B); in addition, the levels of CD4+CD70+ T cells correlated 
with VL within the group of viremic individuals (Figure 11C), indicating a potential contribution 
of high viremia in modulating CD70 expression. 
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Figure 12. T cell activation and proliferation regulates the size of the CD4+CD70+ T cell 
populations. The ratio of the different naïve and memory subsets among CD4+ T cells of HIV-1 infected 
and non-infected controls (ctrl) is shown (A).  CD70 expression was measured on CD45RA+CCR7+ 
naïve, CD45RA-CCR7+ central memory (CM), CD45RA-CCR7- effector memory (EM) and 
CD45RA+CCR7- effector memory (TEMRA) CD4+ T cells of HIV-1 infected and non-infected controls 
(B).  The expression of CD127 (C) and the proliferation marker Ki67 (D) was compared between CD4+ 
CD70+ and CD4+ CD70- T cells from ART-treated patients and from non-infected controls.  
 
Lymphopenic  patients were characterized by a significantly increased frequency of CD4+ TEM 
subset as compared to non-infected controls and the additional groups of HIV-1 infected patients 
(Figure 12A), suggesting that the increased frequency of CD4+CD70+ T cells in lymphopenic  
patients  might be due to an accelerated naïve-to memory differentiation. CD70 was 
preferentially expressed on CD4+ TEM cells, and to a lesser extent, on CD4+ TEMRA, both in 
HIV-1 infected patients and control subjects (Figure 12B); these results indicated that a higher 
CD70 expression in lymphopenic patients may be associated with the increased frequency of 
effector memory CD4+ T cells. CD4+ CD70+ T cells expressed reduced levels of CD127 
(Figure 12C) and increased levels of the proliferation marker Ki67 (Figure 12D) as compared 
with the CD4+ CD70- counterpart, suggesting that CD4+CD70+ T cell frequencies might 
increase in lymphopenic and viremic patients due to accelerated T cell activation. 
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In the course of HIV-1 infection, CD4+ T cell depletion is often associated with increased IL-7 
levels. In the cohort of lymphopenic patients included in the present study we previously 
detected low levels of IL-7 [174]; this result might be explained by the prolonged lymphopenia 
and its harmful effects on lymphoid niches leading to a reduced availability of IL-7 which results 
in increased apoptosis and loss of mainly naive T cells [187]. Importantly, we did not detect any 
correlation between plasma IL-7 levels and CD70 expression; accordingly, CD70 upregulation 
in lymphopenic patients appears to occur independently of circulating IL-7 levels. It cannot 
however be excluded that IL-7 produced locally in lymphoid tissues may be involved in the 
CD70 up-regulation which was noticed in effector memory cells. It is of interest that when 
studying different factors which could be involved in CD70 up-regulation on T cells we found 
that IL-2, IL-7 and TCR triggering led to CD70 up-regulation in T-cells from HIV-1 infected 
patients and controls. 
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Figure 13. CD4+CD70+ T cells produce Th1-type cytokines and express chemokine receptors 
mobilizing them towards sites of inflammation. The production of the cytokines IFNγ, TNFα, IL-2, 
TGFβ, IL-17 and    IL-10 from CD4+ CD70+ and CD4+ CD70- T cells of treated HIV-1 infected patients 
and in non-infected controls was studied, following stimulation with PMA and Ionomycin (A). We also 
evaluated the expression of CCR7, CXCR3, CCR5, CXCR5, CCR9 and CCR10 chemokine receptors on 
these cells (B).  
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CD4+CD70+ T cells of HIV-1 infected patients, as compared with the CD4+ CD70- population, 
produced at a higher frequency the pro-inflammatory cytokines IFN-γ, TNF-α and at a lower 
frequency IL-2 (Figure 13A). The migratory profile of the CD4+ CD70+ T cells included a 
higher expression of CCR5 and CXCR3 as compared with their CD70- counterparts, suggesting 
their homing property to inflamed tissues in both HIV-1 infected and non-infected individuals. 
The low CCR7 and CXCR5 expression indicated that the CD4+CD70+ T cells may act outside 
the lymphoid follicles and the lack of CCR9 and CCR10 expression indicated no selected 
homing properties of the CD4+CD70+ T cells to the intestine or the skin, respectively (Figure 
13B). 
A
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Figure 14. Marker of B cell activation, apoptosis and plasma IgG levels correlate with CD4+CD70+ 
T cell frequencies.  The frequency of CD38 and CD95 expression on B cells and the levels of IgG in 
plasma were measured in specimens from non-infected controls (ctrl) and HIV-1 infected patients (A). 
We analyzed the association between CD4+CD70+ T cell frequencies and the expression of CD38, CD95 
and plasma IgG levels (B) on resting memory (RM), activated memory (AM) and tissue-like memory 
(TLM) B cell subsets in the same groups of individuals. 
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We analyzed whether the increase of CD4+ CD70+ T cell frequencies in circulation can be 
associated with phenotypic alterations of B cells. A higher expression of the activation marker 
CD38 on B cells was detected in both viremic and lymphopenic patients, as compared with non-
infected controls or non-lymphopenic, non-viremic patients (Figure 14A). When all subjects 
were analyzed together, the percentage of CD4+CD70+ T cells correlated with CD38 expression 
on RM B cells and AM B cells (Figure 14B). In addition, CD95 expression among AM and 
TLM B cells correlated with the frequency of CD4+ CD70+ T cells (Figure 14B). These results 
indicated that CD70 expression on T cells may possibly be a driving force for activation of 
memory B cell subsets, as measured by CD38 and CD95 expression.   
The IgG concentration in plasma was elevated in viremic and lymphopenic patients compared 
with non-infected controls (Figure 14A), whereas the levels of plasma IgG in serum of non-
lymphopenic, non-viremic patients were similar to what found in the controls. The frequency of 
circulating CD4+CD70+ T cells correlated with plasma IgG levels when all groups of patients 
and controls were analyzed together (Figure 14B).  Since we found that CD38 expression and 
plasma IgG levels were all upregulated in viremic patients, similarly to what observed in 
lymphopenic patients, it is likely that viremia-induced factors can contribute to the correlation 
noticed between CD4+CD70+ T cells and parameters of B cell activation. However once we 
excluded the viremic patients from our analysis we still found that CD4+CD70+ T cell 
frequency significantly correlated with CD38 expression on RM and AM B cells, CD95 
expression on AM and TLM B cells as well as IgG levels in plasma (supplementary Figure 4 in 
paper III). B cell proliferation was studied in HIV-1 infected individuals and non-infected 
controls and we detected a correlation between Ki67 expression on B cells and CD4+ CD70+ T 
cell frequency. 
In conclusion we found that CD70+CD4+ T cells correlate to CD4+ T cells counts in HIV-1 
infected individuals. While we could not firmly pin-point the mechanism for this CD70 
upregulation it is possible that the inflammatory environment caused by virus replication in 
several lymphoid organs may be at the basis for the upregulation of CD70 molecule on T cells. 
CD70+CD4+ T cells were mostly found among highly differentiated TEM and TEMRA cells.  The 
expression of CD70 on CD4+ T cells correlated to activation markers present on populations of 
memory B cells and serum IgG levels. It is of interest that in patients with SLE, a disease 
characterized by abnormal activation of B cells and autoantibody production, an increased 
frequency of CD70+CD4+ T cells is found [188]. HIV-1 infection leads to increased production 
of circulating IgG; although a detailed characterization of the specificity of these antibodies is 
still missing it is believed that a large portion of circulating IgG during HIV-1 infection may 
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represent auto-antibodies with unknown targets. These findings create an interesting parallel 
between the auto-immune disease SLE and the chronic HIV-1 infection.  
If CD70+CD4+T cells have a role in B cell activation, as suggested by the ex-vivo analyses 
shown in paper III, it is unclear at which site CD70+ CD4+T cells promote B cell activation. 
As CD70+CD4+T cells appears to be equipped with chemokine receptors ensuring their 
migration to inflamed tissue, one possibility is that CD70+CD4+T cells promote B-cell 
activation in inflamed tissues.  
 
5.4 Paper IV - ART initiated during primary HIV-1 infection and its 
impact on the establishment of abnormal phenotypic features of 
CD4+ and CD8+ T cells 
 
Although ART can achieve a complete or nearly complete suppression of HIV-1 replication, 
prevent AIDS and reduce overall mortality, antiviral drugs do not fully target immune activation 
and residual immune activation persists even after many years of viral suppression [129, 133, 
189]. Chronic immune activation is considered to be the driving force of HIV-1 pathogenesis 
and is giving rise to phenotypic dysfunctions in HIV-1 specific and non-HIV-1 specific CD4+ 
and CD8+ T cells [133]. The phenotypic dysfunctions include distinct or combined features of 
abnormal immune activation, senescence and inhibition of immune responses. In this cross-
sectional study, we included two groups of HIV-1 infected patients who had previously begun 
ART during PHI or in the chronic phase of infection. We aimed at investigating whether early 
ART initiation prevents the establishments of abnormal phenotypic features reported in CD4+ 
and CD8+ T cells of patients treated in the chronic phase of infection. 
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Figure 15. CD4+ T cell counts (A) and CD4/CD8 ratio (B) in individuals receiving ART during 
early and late phases of HIV-1 infection. EA=early ART; LA=late ART. The measurements were 
performed before ART initiation at baseline (BL), at 12 months (12m) from ART initiation and at 
sampling (S).  
 
The early treated group, EA and the late treated group, LA, both consisted of 17 patients (16 
males: 1 female); the mean age and SD was 43.8± 14.9 for the EA group and 42 ± 11.2 for the 
EA group. At the time of specimen collection, both patient groups had received treatment for a 
comparable period of time; individuals in the EA group had been treated for 25 months (range 7-
59) and individuals in the LA group for a median of 29 months (12-60). In the cohort of EA 
patients, 11 were classified as Fiebig stage II, 3 as stage IV and 3 additional patients as stage V. 
The control group, named C, consisted of 25 non-infected subjects (all men); in this control 
group the mean age and SD was 40.4 ±14.0. 
 
At baseline, CD4+ T cell counts were lower in the EA group, as compared with the LA group; at 
seroconversion, the time-point when viremia peaks, there is often a massive depletion of CD4+ 
T cells. In addition, at baseline, the virus titers in the EA group were higher than in the LA 
group, with a HIV-1 RNA value (copies/ml) of 5.97 log in the EA group as compared with 4.57 
log in the LA group. At 12 months from the initiation of ART and at time of sampling, the virus 
was undetectable (<20 copies/ml) in the blood of all HIV-1 infected individuals. As assessed by 
the clinical records, the absolute numbers of CD4+ T cells increased in both the EA and LA 
groups at 12 months after initiation of ART. At the time of sampling, CD4+ T cell count had 
further increased in both groups of patients (Figure 15A). 
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The median CD4/CD8 T cell ratio increased over time in both the EA and LA groups; however 
the increase was more significant in the EA group, and the median CD4/CD8 T cell ratio in the 
LA group never reached the value of 1 or above at the time point for sampling (Figure 15B). 
Low numbers of naïve and circulating CD4+ T cells, high numbers of differentiated memory 
CD8+ T cells and chronic inflammation are associated with immunosenescence in elderly 
people, features also common in HIV-1 infection [89, 190]. A low CD4/CD8 ratio is associated 
with T cell activation, senescence, and chronic inflammation [191, 192] and has also been linked 
to a poor prognosis in ART-treated HIV-1 infected individuals [193]. A role for CD4/CD8 T cell 
ratio as a morbidity biomarker has been proposed as a recent study showed that, in spite of 
CD4+ T cell count normalization in the majority of patients on long-term ART, an increased risk 
of mortality still persists for this group of patients; this risk might be predicted by the persistence 
of a low CD4/CD8 T cell ratio in spite of increased CD4+ T cell counts [194]. Another study 
showed that the CD4/CD8 T cell ratio correlated with increased frequencies of CD4+ T cells 
expressing the activation markers CD38 and HLA-DR and the inhibitory receptor PD-1 [195], 
highlighting the CD4/CD8 T cell ratio as a surrogate marker for CD4+ T cell dysfunction in 
HIV-1 infection. 
 
We studied the frequency of total CD4+ and CD8+ T cells and their subpopulations in blood. 
The frequencies of CD4+ T cells in the LA group were significantly lower as compared with the 
control subjects. The frequency of total CD8+ T cells was higher in both patient groups as 
compared with controls. The frequencies of TEMRA CD4+ T cells were statistically increased 
in the EA and LA groups as compared with controls. Among CD8+ T cells, the frequencies of 
TEMRA+ cells in the LA group were significantly higher as compared with the control group. 
Of note, no difference was detected for the frequencies of the studied CD4+ and CD8+ T cell 
populations between the EA and LA groups. 
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Figure 16. Frequency of CD38++ CD4+, HLA-DR+ CD4+ and CD127- CD8+ T cell subsets. The 
frequency of CD38++ and HLA-DR+ cells among total, naïve, central memory (CM), effector memory 
(EM) and  effector memory CD45RA+(TEMRA) CD4+ T cells is shown, together with the frequency of 
CD127- total, naïve, CM, EM and TEMRA CD8+ T cells. 
 
 
The expression of different CD4+ and CD8+ T cell markers associated with HIV-1 pathology 
was studied. These included immune activation (HLA-DR, CD38), senescence (CD28, CD57) 
exhaustion (PD-1) and terminal differentiation (CD127).  A higher frequency of total CD4+ T 
cells, naïve, CM and EM CD4+ T cells from the EA group were HLA-DR+ as compared with 
the corresponding cells and subpopulations in the control group. When comparing the two 
groups of HIV-1 infected individuals, a higher frequency of HLA-DR+ naïve CD4+ T cells was 
found in the circulation in the EA group as compared with the LA group. In addition, higher 
levels of total CD4+ T cells, CM and EM CD4+ T cells from both patient groups were CD38++ 
as compared with controls. A higher frequency of CD127- cells was found in total CD8+ T cells 
and in all subpopulations of CD8+ T cells of EA and LA as compared with the control group 
(Figure 16). Markers used for identifying senescent cell populations were both upregulated in 
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different CD4+ T cell populations in the LA patient group; a larger frequency of CD28- total, 
EM and TEMRA CD4+ T cells were identified in the LA group as compared with the control 
group. In addition, CD57 was also expressed at higher levels on EM and TEMRA CD4+ T cells 
from the LA group versus control group. 
 
A
B
EA
LA
 
 
Figure 17. Activated CD4+T cells in HIV-1 infected patients are associated with CD4 +T cell 
counts. In specimens from LA patients, the frequency of HLA-DR+ total, EM and TEMRA CD4+T 
cells, and CD38++ total, naïve, CM and EM CD4+ T cells inversely correlated with lower CD4 T cell 
counts/μl (A). In specimens from EA patients, the frequency of HLA-DR+ in total and CM CD4+ T cells 
and CD38++ CM CD4+ T cells inversely correlated with CD4+ T cell counts/μl (B).   
 
Ki67 is an intracellular marker widely used to characterize proliferating cells. A larger frequency 
of CM and EM CD4+ T cells from both HIV-1 patient groups expressed Ki67, as compared with 
the control group. Furthermore, an indirect correlation was found between the CD4+ T cell 
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counts and the frequency of Ki67+ total CD4+ T cells, Ki67+ CM CD4+ T cells and Ki67+ EM 
CD4+ T cells from LA patients. Similarly, CD4+ T cell counts from the same LA group 
inversely correlated with frequency of Ki67+ total CD8+ T cells, Ki67+ CM CD8+ T cells and 
Ki67+ EM CD8+ T cells. These results suggest that proliferating T cells may have a negative 
effect on the absolute CD4+ T cell number, even in treated patients. 
We measured the levels of soluble markers of immune activation and inflammation in plasma. 
Significant levels of inflammatory markers distinguishing the groups of patients from one 
another could not be detected, which is likely due to the positive effect of ART in both groups of 
patients. However, the levels of sCD14 were significantly higher in the group of EA patients as 
compared with the control group; the median levels of sCD14 were also higher in the LA group 
compared to controls although did not reach a significant difference.  Furthermore, the levels of 
β2M were higher in the LA group as compared with the control group. β2M has been shown to 
be increased during HIV-1 infection and released by activated T cells [146], data consistent with 
our findings on persistent T cell activation.  
In the LA group, the expression of HLA-DR+ and CD38++ in most CD4+ T cell subpopulations 
negatively correlated with the CD4+ T cell counts (Figure 17A). In the EA group, HLA-DR+ 
total and CM CD4+ T cells and CD38++ CM CD4+ T cells inversely correlated with the CD4+ 
T cell counts (Figure 17B). The lack of CD127 expression on CD8+ T cells and CD8+ T cell 
subpopulations from the EA group inversely correlated with the CD4/CD8 T cell ratio, whereas 
lack of CD127 expression on CD8+ T-cell subpopulations from the LA group did not correlate 
with this parameter. It has been shown that CD4+ T cell counts often fail to return to normal 
levels and inflammation and T- cell activation remain elevated during ART administration [103, 
189]. Also in our study, the expression of the activation markers HLA-DR and CD38 were 
upregulated on CD4+ T cells and inversely correlated with the CD4 + T cell counts, supporting 
the observation that the high activation levels of T cells are independent predictors of CD4+ T 
cell decline and progression to AIDS and therefore a continuous driving force fueling HIV-1 
pathogenesis [196]. 
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Figure 18. Size of total  HIV-1 DNA copies and its correlation to T cell subpopulations and surface 
markers. Copies of HIV-1 DNA in PBMCs from EA and LA patients (A). In specimens from EA 
patients, the number of HIV-1 DNA copies was shown to directly correlate with the frequencies of CD8+ 
EM and CD8+ total HLA-DR+ T cells, whereas a negative correlation was shown between the size of 
virus reservoir and the frequency of CD8+ TEMRA T cells (B). In specimens from LA patients, the 
number of HIV-1 DNA copies, directly correlated to the frequency of CD8+ CM PD-1+ T cells and 
indirectly to the CD8+ TEMRA CD38++ T cells (C). 
 
 
We determined the size of the virus reservoir in EA and LA patients by the quantification of 
total HIV-1 DNA in PBMCs. The copies of HIV-1 DNA detected in PBMCs of EA patients 
treated during the acute phase of infection were significantly lower than what was found in LA 
patients treated during the chronic phase of infection (Figure 18A). This result confirms a 
previous study on the beneficial effect of early ART on confining the establishment of virus 
reservoirs [197]. A positive correlation was found between the total HIV-1 DNA copies of EA 
patients and the frequencies of CD8+ EM and CD8+HLA-DR+ T cells, whereas an indirect 
correlation was detected with CD8+ TEMRA+ T cells (Figure 18B). In the LA group, the copies 
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of HIV-1 DNA correlated with the frequencies of CD8+ CM PD-1+ T cells and inversely with 
CD8+ TEMRA CD38++ T cells (Figure 18C). It is not surprising that PD-1 and HLA-DR, 
markers of exhaustion and immune activation respectively, directly correlated with the size of 
HIV-1 DNA as they might be involved in sustaining virus replication by suppressing immune 
functions. 
We have shown that features of immune activation, exhaustion and terminal differentiation are 
present on CD4+ and CD8+ in patients treated during PHI. Their dysfunctional phenotype does 
not distinguish them from patients who started ART during the chronic phase of infection. 
Importantly, these abnormalities are similar in the two patient groups despite the significant 
difference in the number of total HIV-1 DNA copies in PBMCs, with lower amounts in EA 
patients. In addition, it cannot be excluded that despite successful ART, the size of the virus 
reservoir may be different in relevant lymphoid tissues where the abnormal immune activation 
takes place. It is highly relevant to identify biomarkers which may predict immunological 
preservation in patients treated during PHI; these patients may be part of cohorts selected to 
assess new therapy to cure HIV-1 infection. 
 
5.5 Preliminary results - Frequency of B cell sub-populations in the 
blood of EA and LA HIV-1 infected patients 
 
Many of the B cell defects described to occur in HIV-1 viremic individuals can be improved 
with ART, although the normalization of the frequency of some B cell subsets has been shown 
to be slow and incomplete in patients initiating ART during the chronic phase of infection [152, 
176, 177]. We aimed at investigating the frequency of B cell subsets in our cohort of early and 
late treated HIV-1 patients included in paper IV. Our group and others have previously shown 
that ART initiation in the early phase of HIV-1 infection is associated with improved B cell 
memory function as measured by memory B cell responses to different recall antigens in both 
adults and children [167, 170]. 
As compared to non-infected individuals, LA patients exhibited a significant decrease of total B 
cell frequency as compared to controls, a finding which was not present in the group of EA 
patients (Figure 19). We could not find any significant difference between the groups of  HIV-1 
infected subjects and controls in relation to the frequencies of IT, Naïve, RM, AM, TLM and 
MZ-like (CD19+CD10-CD27+IgM+IgD+) B cells. There was however a tendency for AM B 
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cells to be higher in the groups of HIV-1 infected subjects (6.64±4.33, 6.82±3.83 and 4.4±2.01 
in EA, LA and control subjects respectively) as compared to controls, (Figure 19A). 
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Figure 19. B cell phenotype of early and late treated HIV-1 infected patients. The phenotype of B 
cells was assessed on PBMCs from EA and LA HIV-1 infected patients and in non-infected subjects.      
B cell subpopulations were gated on living CD19+ B cells as detected by the Live/Dead kit labeled with a 
near-infrared dye. Frequency of total B cells (CD19+), immature transitional (IT) B cells, naïve B cells, 
resting memory (RM) B cells, activated memory (AM) B cells, tissue-like memory (TLM) B cells and 
MZ-like B cells (A) as previously reported [155]. Levels of BAFF were measured in plasma samples by 
ELISA (B). Statistical analyses were performed using Kruskal-Wallis test followed by Dunn’s post test. 
 
It was surprising that the frequency of B cell subpopulations was not significantly different in 
the LA group as compared to controls; however this group of patients initiated treatment at a 
median CD4+ T cell count of 530 cells/µl which is relatively high compared to patients included 
in previous studies; the EA patients began ART at a median CD4+ T cell count of 430 cells/µl. 
That the frequency of B cell sub-populations was not different between patients in the EA group 
and control was less surprising, as the hope is to prevent immunological impairment by 
administrating ART during PHI. One limitation of our study is that the number of included 
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patients is low; the significance of our results may become more clearly by increasing the 
number of EA and LA patients. In addition we did not follow the patients longitudinally from 
the time of ART initiation.  
Among the soluble factors analyzed in serum of the two groups of EA and LA patients and 
controls, we also measured the levels of BAFF.  It was interesting that the levels of BAFF in our 
cohorts of EA and LA HIV-1 infected patients were significantly increased compared to 
controls; this difference was more pronounced between the LA group and controls (Figure 19B).  
It has previously been shown that BAFF is increased in the serum of HIV-1 infected patients; the 
increased level of BAFF was in some cases associated with viremia [198, 199] and also persisted 
in patients despite successful ART [200].  
 
Figure 20. Frequencies of total and memory B cell sub-populations and their correlation with 
BAFF levels. We analyzed the potential correlation between the frequencies of circulating B cell sub-
populations with the levels of BAFF in plasma from both EA and LA HIV-1 infected patient groups and 
controls. Data were analyzed using Spearman correlation test. 
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We related the frequency of B cell sub-populations in the whole group of EA and LA patients 
and controls to BAFF levels and the results of these correlations are shown in Figure 20. A 
positive correlation was found between the levels of BAFF and total B cells, AM B cells and 
TLM B cells. The role of BAFF in B cells dysfunctions during HIV-1 infection has not been 
thoroughly studied. A study conducted in SIV-infected RM, which exhibited elevated  levels of 
BAFF, showed a consistent B cell polyclonal activation detected by IgM and IgG 
hyperglobulinemia and a significant increase in the relative frequencies of AM B cells and 
exhausted TLM B cells [215]. That elevated BAFF levels can be found in successfully ART-
treated individuals suggest that early ART does not correct for this abnormality which may be 
consequence of persistent HIV-1 infection and chronic immune activation. 
BAFF has been described as an important molecule in the context of SLE, as blocking of this 
molecule through a monoclonal antibody targeting BAFF ameliorates disease activity [79, 201]. 
Even in the context of SLE is not completely clarified the role of BAFF in mediating a disease 
characterized by alterations in B cell tolerance, caused by defective tolerance check-points. 
Excess of BAFF rescues autoreactive anergized cells and promotes their maturation into 
follicular or MZ B cells [201].      
The mechanism leading to increased circulating levels of BAFF during HIV-1 infection is 
unknown. A recent study described a role for the viral factor Nef  in promoting the high 
expression of BAFF by dendritic cells in the blood of HIV-1-infected  individuals receiving 
ART, suggesting a role for persistent HIV-1 infection in driving the upregulated levels of BAFF 
in circulation [202]. It is interesting that in our cohort of EA patients, where the size of virus 
reservoir is limited and virus replication cannot be detected in blood, high levels of BAFF were 
anyway detected in circulation. A recent study highlighted the importance of macrophages as a 
source of BAFF since they are among the first cell populations targeted by the virus, following 
PHI. Once macrophages are infected they display an altered production of cytokines/chemokines 
which contributes to the general state of immune activation during HIV-1 infection, likely to 
affect both T and B cells [203]. 
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6 CONCLUSIONS AND FUTURE DIRECTIONS 
 
Within the first weeks of HIV-1 infection, the massive CD4+ T cell depletion taking place in the 
GALT is contributing to the impaired regulation of the epithelium and breakdown of the 
mucosal barrier. The severity of CD4+ T cell depletion is associated with microbial 
translocation, chronic immune activation and disease progression in HIV-1 infected individuals 
[104, 105]. Initiation of ART leads to suppression of HIV-1 replication in a large majority of 
patients, thus improving the immune function and nearly eliminating the risk of AIDS-related 
complications. Effectively treated HIV-1 infected individuals are, however, at higher risk of 
non-AIDS related morbidity than age-matched HIV-1 non-infected adults [31, 204].  
Specimens from the patients included in my studies were collected starting in 2009; at that time 
point our clinical collaborators in Stockholm still followed several patients who did not receive 
ART as their CD4+ T cell counts was above 350 cells/µl. The situation is different today as in 
Sweden, following recent recommendation from WHO, HIV-1 infected patients will receive 
ART independently of their CD4+ T cell counts as soon as their HIV-1 status will become 
known. This is obviously a fantastic opportunity for the clinical management of HIV-1 infection 
as ART will confine inflammation and immune activation, thus ultimately leading to a healthier 
life for HIV-1 infected patients. This poses however some problems to conduct studies 
addressing the natural history of HIV-1 pathogenesis. Accordingly when discussing future 
perspectives within the frame of the studies which I have conducted, it has to be taken in account 
that specimens can only be obtained from ART treated patients.  
In paper I, we found an increased expression of IL-21R on classical memory B cells 
(CD19+CD10-CD27+) and TLM cells from viremic HIV-1 infected patients. The expression of 
the IL-21R on RM B cells was shown to correlate with their decreased frequency in the 
circulation of HIV-1 infected patients, suggesting that IL-21R expression on B cells may play a 
role in compromising the survival of these cells.  In line with this possibility, IL-21R positive B 
cells were found to be more susceptible to apoptosis, as shown by lower Bcl-2 expression. We 
unraveled two mechanisms which could lead to up-regulated expression of IL-21R during HIV-
1 infection. Several TLR agonists directly triggered the expression of   IL-21R on B cells and, in 
addition, the elevated levels of sCD14 in circulation correlated with IL-21R expression on RM B 
cells and the decreased levels of these cells in circulation. We also described an increased 
activation of B cells from HIV-1 infected individuals, as measured by CD38 expression on total 
and classical memory B cells, which was associated with HIV-1 replication. CD4+ T cell counts 
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were found to be inversely correlated with CD38 expression on B cells; this correlation was 
stronger in viremic patients and HIV-1 viral load was also shown to directly correlate with 
CD38 expression on B cells in HIV-1 patients. These findings suggest that microbial 
translocation and associated immune activation may contribute to loss of memory B cells during 
HIV-1 infection. 
It is unclear whether the increased frequency IL-21R positive B cells in HIV-1 infected patients 
corresponds to an increased signaling through this receptor; it is highly possible that increased 
IL-21R expression only reflects activation of B cells by microbial components as shown in paper 
I. We measured the levels of IL-21 in serum and found that this cytokine was present at a 
reduced level in the plasma of HIV-1 infected subjects, independently of ART, as compared to 
controls. During the time our study was conducted another group reported the same finding on 
reduced level of IL-21 in HIV-1 infection [205]. Tfh cells are important producers of IL-21 and 
a reduced level of circulating IL-21 could reflect a reduced capacity of Tfh cells to produce IL-
21. It would be of interest to assess IL-21 production by Tfh cells in parallel to IL-21R 
expression in specimens from HIV-1 infected patients to understand whether these two 
parameters are interconnected. This point may be difficult to be addressed in the future as the 
majority of patients receive ART; in paper I IL-21R expression in ART treated patients returned 
to level similar to what found in the controls. 
The cytokine IL-7 was shown to indirectly affect B cell activation and survival, as described in 
paper II. We demonstrated that IL-7 is able to upregulate CD70 expression on T cells; this 
event, in turn, through the triggering of CD27 receptor on B cells, led to proliferation of B cells 
that displayed a phenotype of differentiated cells and secreted high levels of Igs. These effects 
were abrogated by CD70 blocking experiments. In addition, IL-7 was shown to increase BAFF 
production by T cells, which enhanced B cell survival; when blocking BAFF signaling, B cell 
apoptosis increased. Our data suggest that IL-7 can enhance the B cell stimulatory potential of 
resting T cells via the upregulation of CD70, possibly contributing to a generalized B cell 
activation in conditions associated with elevated IL-7 levels, including HIV-1 infection.  
The results of  paper II are surprising and important as we showed that upregulation of CD70, 
induced by IL-7, leads to B cell activation and immunoglobulin production in absence of any 
specific antigen. It is possible that in diseases accompanied by an elevated IL-7 production, as 
SLE and HIV-1 infection, augmented CD70 expression on T cells may lead to a generalized 
activation of B cells independently of their specificity. This observation highlights similarities 
between the pathogenesis of SLE and dysregulated B cell responses during HIV-1 infection. 
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Paper II also highlighted the possibility that activated T cells may participate in vivo to BAFF 
production, a property previously assigned to BM stromal cells and APCs.   
I continued by studying whether the mechanism presented in paper II could account for some of 
the B cell dysfunctions, including hyperactivation, described to take place during HIV-1 
infection [155]. In paper III, we found an increased expression of CD70 on CD4+ T cells in 
correlation with CD4+ T cell depletion or viremia in HIV-1 infected patients. Surprisingly, we 
could not detect any correlation between plasma IL-7 levels and CD70 expression, suggesting 
that the CD70 upregulation in CD4+ T cell depleted patients may be independent of IL-7. In 
earlier work [168], it was shown that high level of IL-7 during HIV-1 infection inversely 
correlated with CD4+ T cell counts. While ART leads to an increased CD4+ T cell number, it is 
not clear whether high IL-7 production takes place in lymphoid tissues of treated patients; on the 
contrary it has been shown that production of IL-7 from lymphoid tissue may be permanently 
affected, due to collagen deposition which begins at the early phase of infection [136]. Based on 
their chemokine profile, we could show that CD4+ CD70+ T cells produce ex-vivo pro-
inflammatory cytokines and have the potential to migrate to sites of inflammation. In addition, a 
putative role for CD70+ CD4+ T cells in providing bystander help for B cell activation was 
suggested in paper III by the association between the increased frequency of CD4+ CD70+ T 
cells and higher CD38 and CD95 expression on memory B cells, as well as increased B cell 
proliferation and plasma IgG levels in HIV-1 infected individuals. These results highlight the 
possible role of peripheral CD4+ CD70+ T cells in providing B cell stimulatory signals which 
may contribute to increased B cell activation, a characteristic of HIV-1 infection.  
It would have been of interest to expand this study by further characterizing the properties of 
CD70+CD4+ T cells and by asking whether these cells express markers of immune activation, 
typically found during HIV-1 infection.  The measurements of BAFF expression in T cells and 
soluble BAFF in plasma would also lend support to the mechanism presented in paper II which 
leads to B cell activation.  A relevant aspect to study further is whether IL-7 is still produced in 
the LTs of HIV-1 infected patients to a higher level than what can be found in healthy controls. 
This latter study could clarify the factors leading to CD70 up-regulation on CD4+ T cells during 
HIV-1 infection. As previously mentioned it is difficult to conduct studies on viremic HIV-1 
patients as the majority of patients in the clinics in Stockholm receive ART and become 
aviremic. However as we found that a higher frequency of CD70+CD4+ T cells was found in 
the blood of patients who remained significantly lymphopenic in spite of ART for several years, 
these studies could be conducted in a few individuals of lymphopenic patients.  
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In paper IV, we show that ART initiation during PHI did not prevent phenotypical changes of T 
cells, which were comparable with the dysfunctional phenotype identified in HIV-1 infected 
patients starting treatment during the chronic phase of infection. The major phenotypical 
changes identified were related to increased immune activation (HLA-DR+ and CD38++ mainly 
on CD4+ T cells) and the down-regulation of CD127 (on CD8+ T cells and subpopulations).  In 
contrast to the dysfunctional phenotypes identified in both groups of HIV-1 infected patients, the 
number of HIV-1 DNA copies found in blood of EA patients was significantly lower than what 
was measured in LA patients. It cannot be excluded that despite successful ART, the size of the 
virus reservoir may be different in relevant lymphoid tissues where some virus replication may 
still take place [206], accompanied by abnormal immune activation. A clear limitation to this 
study presented in Paper IV is that the EA and LA patients were not followed from the time of 
ART initiation; accordingly we do know about the size of virus reservoir at ART initiation in 
these EA and LA patients. In addition we have not studied if the levels of immune activation 
were comparable in both groups at the time of ART initiation.     
We measured several soluble parameters of inflammation in blood (Paper IV) and found that the 
levels of these molecules did not distinguish between EA and LA patients; in general the levels 
of these inflammation parameters did not distinguish between HIV-1 infected and controls. It 
was a real surprise to find elevated levels of BAFF in the serum of HIV-1 infected individuals, 
both EA and LA, compared to controls (preliminary results) and that BAFF levels correlated in 
the whole group of patients and controls to memory B cell populations which frequency is 
dysregulated during HIV-1 infection. The role of BAFF in affecting the biology of B cell sub-
populations during HIV-1 should be further studied.  
In recent years an increased number of HIV-1 infected patients have got access to ART in low-
and middle-income countries [4].  HIV-1 infection and its treatment are associated with a series 
of biological events (e.g. inflammation, immune dysfunction), clinical factors (e.g. 
polypharmacy, multi-morbidity) and social factors (stigmatization) all influencing aging; the 
population of aging ART-treated individuals will therefore confront significant challenges [89, 
207, 208]. The impact that the chronic low-level of immune activation will have on the 
immunological system of ART treated adults, now expected to live for decades, is not known 
[204]. The recently published START study [36] showed many health benefits in patients 
initiating ART during the asymptomatic phase of HIV-1 infection.  The VISCONTI cohort study 
[212] is a good example of the benefits of early treatment initiation and how that can result in 
more individuals becoming post-treatment controllers for a variable period of time when 
interrupting ART. 
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These findings, in combination with the escalating cost for treatment in countries with high 
number of HIV-1 infected individuals, has promoted scientists operating in the HIV-1 field to 
investigate novel strategies for a HIV-1 cure [223]. Clearly, a cure strategy would both benefit 
infected individuals and reduce the economic burden for affected countries [224]. It should be 
emphasized that there is an urgent need to identify biomarkers to characterize immune-
preservation in patients initiating ART during PHI; these may help to pin-point patients who 
may be taken off from ART and be included in future studies for cure intervention.  
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7 MATERIALS AND METHODS 
 
Study populations  
The patient material included in papers I, III and IV and material from HIV-1 uninfected donors 
consisted of blood samples collected in collaboration with the HIV-1 clinic Venhälsan at 
Stockholm South General Hospital, Sweden. 
Paper I 
Peripheral blood was collected from healthy subjects (n=23) and HIV-1 infected patients (n=40). 
Among HIV-1 infected patients, 20 were undergoing ART and started treatment in the chronic 
phase of infection [mean duration of infection: 13.5 (1.5-25) years; duration of treatment: 8.15 
(1.5-17) years, CD4+ T cell count: 619 (222-1412) cells/ml and HIV-1 RNA <50 copies/ml] and 
20 were naïve to treatment [mean duration of infection: 5.4 (1.5-12.5) years; CD4+ T cell count: 
600 (278-1357) cells/ml and HIV-1 RNA 33960 (233- 132 000 copies/ml]. 
Paper II 
Peripheral blood mononuclear cells (PBMCs) were separated from buffy coats collected from 
healthy blood donors at the Karolinska University Hospital, Solna, Sweden. 
Paper III 
Blood samples were obtained from healthy donors (n=10) and HIV-1 infected patients (n=55) 
divided into three different cohorts; 20 patients were naïve to treatment [CD4+ T cell counts 
higher than 350 cells/μl (mean = 600 ± 271 cells/ μl) and HIV-1 RNA 21500 (200-132000)], 25 
patients received ART [CD4+ T cell counts higher than 200 cells/μl (mean 497 ± 222 cells/ μl 
and HIV-1 RNA < 25 copies/ml] and the third group consisted of ten CD4+ T cell lymphopenic 
patients undergoing ART [CD4+ T cell counts lower than 200 cells/μl (mean = 145 ± 65 cells/ 
μl)  for a period of 3-20 years and HIV-1 RNA <100 copies/ml]. 
Paper IV and preliminary data 
Blood samples were collected from healthy controls (n= 25) and HIV-1 infected patients (n=34). 
Amongst the HIV-1 infected patients, 17 patients started ART treatment during PHI [median 
duration of treatment: 25 (7-59) months, CD4+ T cell count: 840 (390-1340) cells/ml and HIV-1 
RNA <50 copies/ml], and 17 patients started treatment in the chronic phase of infection [median 
 
 
61 
 
duration of treatment: 29 (12-60) months, CD4+ T cell count: 780 (250-1000) cells/ml and HIV-
1 RNA <50 copies/ml]. 
 
Isolation of PBMCs from HIV-1 infected patients and healthy controls 
(all papers) 
A high-density centrifugation technique was used in order to isolate mononuclear white blood 
cells from whole blood. 15 ml of sodium chloride solution containing high molecular weight 
sucrose-polymers was poured into a 50 ml tube. The blood sample was then carefully applied on 
top of the solution, and the tube centrifuged without brake for 20 minutes at 2000 rotations per 
minute (rpm). The layer of mononuclear cells was then transferred to a new tube, with the help 
of a pipette. The cells were washed a few times in Phosphate Buffer Solution (PBS) and once in 
Roswell Park Memorial Institute (RPMI) medium. The RPMI medium used in all assays 
included L-Glutamine, Sodium pyruvate, HEPES buffer and high glucose and completed with 
10% fetal calf serum (FCS) and 1% penicillin- streptavidin-fungizone solution. PBMCs were 
cryoperserved in FCS with 10% dimethylsulphoxide (DMSO) in liquid nitrogen (-196°C) until 
further analyses were conducted. 
 
Cell culture  
In vitro B cell activation through BCR and TLRs (paper I) 
PBMCs and purified B cells from healthy donors were cultured in RPMI medium in the 
presence of different TLR agonists and anti-BCR for 24 hours. 
Co-culture of IL-7 pre-treated peripheral T cells and B cells (paper II) 
T cells and B cells were separated from PBMCs with microbeads using Pan T cell Isolation Kit 
and B cells isolation kit II respectively. Purified cells were cultured in RPMI medium and pre-
treated with recombinant IL-7 for 5 days. For T cells -B cells co-culture, a ratio of 1:1 T cells-B 
cells was used. 
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In vitro CD70 upregulation with different stimuli associated with chronic HIV-1 
infection (paper III) 
PBMCs of non-infected individuals and ART-treated non-lymphopenic patients were stimulated 
with a HIV-1 strain, inflammatory cytokines, γ-chain cytokines and a T cell receptor cross-
linking antibody for 5 days. 
 
Flow cytometry (all papers) 
Flow cytometry is a method that enables multiple and quantitative evaluation of millions of 
heterogeneous immune cells based on light scattering and fluorescence. In a flow cytometer, the 
high flow generates a single-cell stream of cells that passes laser beams. The size of each cell is 
predicted by how the light is scattered before quantification by a front filter (forward scatter), 
and the light scatter on a side filter (side scatter) measures the cell granularity. The laser induces 
excitation of fluorescent parts on the cells, and the emitted light is captured and measured. 
Antibodies conjugated to fluorescent molecules attach to specific proteins on the cell surface and 
therefore information about several markers of interest can be detected on each cell.   
 
Enzyme-linked immunosorbent assay (ELISA) (all papers) 
ELISA is a method for quantification of cytokines and other analytes in solution. A 
specific antibody was used to coat a microtiter plate. After addition of the sample, the 
specific antibody on the plate will capture the protein of interest, while a second antibody, 
which is used for detection, binds a different epitope on the same protein. The detection 
antibody is labeled with biotin, which allows subsequent binding of a streptavidin-
conjugated enzyme. Any unbound reagent is removed by washing. After addition of a 
substrate, a color reaction develops that is directly proportional to the amount of protein 
bound. The concentration of the protein in the sample is determined by comparison with a 
standard curve of known protein concentrations. 
To quantify antibodies in plasma or serum, plates were coated with the selected antigen. Binding 
of antibodies to the selected antigen was detected by a secondary anti-Ig detection antibody, 
directed towards the immunoglobulin type of interest. In the papers included in this thesis, IgA, 
IgM and IgG were detected. 
 
 
63 
 
HIV-1 infection of humanized mice (paper III) 
Humanized NOD scid gamma (NSG) mice, are a strain of inbred laboratory mice that lack 
mature lymphocytes. When 4-6 weeks old, the mice were conditioned with two intraperitoneal 
injections of Busulfan, which is an alkylating agent used to inhibit the reproduction and growth 
of white blood cells, followed by an injection of freshly isolated human cord blood CD34+ 
hematopoietic stem cells. Mice were screened for cell engraftment by monitoring human CD45 
expression in the peripheral blood. The humanized mice were after 174 up to 195 days of 
transplantation infected with HIV-1 (strain BaL-1, 10 000 TCID50) by intravenous injection.  
Three months post-infection, the mice were anesthetized through an intraperitoneal injection. 
Blood samples were collected via cardiac puncture and cervical dislocation was used for 
secondary euthanasia. VL was measured from plasma; lymph nodes and bone marrow were 
dissociated with syringes and passed through a nylon strainer to obtain single-cell suspensions 
for flow cytometry.  
 
Measurement of total PBMC HIV-1 DNA (paper IV) 
PBMC DNA was obtained by manual extraction. Total PBMC HIV-1 DNA was quantified 
using a homemade Taqman real-time assay with primers located in conserved regions of the the 
HIV-1 genome. To correct for minor deviations from the expected DNA input, total   HIV-1 
DNA copy numbers were normalized on a beta-globin standard curve and expressed as copies 
per million PBMCs. To ensure accurate normalization, HIV-1 and beta-globin DNA were 
amplified in the same reaction tube. The standard curve for quantification of total HIV-1 DNA 
was obtained from serial dilutions of the pNL4-3 plasmid containing the full HIV-1 genome. 
The proviral DNA copy number, combined with the total number of cells present, can give an 
estimate of the frequency of cells harboring HIV-1 DNA. The limit of detection was 10 HIV-1 
DNA copies per million PBMCs. 
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